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Abstract 
 
2A sequences are short 20 ~30 amino acid peptides initially characterised from foot and 
mouth disease virus (FMDV), but also encoded in a range of Picornaviruses and other 
viruses as well as non-LTR retrotransposons in a broad range of organisms. They direct 
a translational recoding event in which ribosomes that have reached the final codon of 
the 2A sequence pause and terminate translation in the absence of a stop codon and then 
restart translation. The effect is to separate a single ORF into 2 polypeptides, between 
the final 2 amino acids (glycine and proline) of 2A, ‘skipping’ a peptide bond. 2A 
sequences comprise 2 parts, a conserved GDV/IEXNPGP C-terminal motif, and a 
highly variable, but necessary, N-terminal portion. In the work described in this thesis, 
extensive mutagenesis studies were carried out across both the conserved and 
non-conserved portions of the FMDV 2A peptide, including alanine, glycine and proline 
scanning mutagenesis, site-directed mutagenesis screens. These data indicate that while 
the amino acid present at the first 2-3 positions of the peptide is not critical for activity, 
the residue at most other positions is important, including several positions that vary 
considerably between different 2A peptides. Intriguingly, results of alanine, glycine and 
proline scanning mutagenesis were very similar, suggesting that features of side chains, 
and not just the secondary structure propensity of the peptide, plays a critical role. 
Despite their great variability, each 2A peptide must provide a set of interactions 
between side chains within the peptide and with the ribosomal exit tunnel to allow the 
2A reaction to proceed. Finally, the work also verified a previous finding that insertion 
of a stop codon in place of the final proline codon of 2A leads ribosomes to stall, unable 
to terminate translation. Efforts were made to establish a system for purification of such 
stalled ribosome-nascent chain complexes towards the eventual aim of structural 
characterisation. The data strongly support a model in which the interaction of the 2A 
peptide with the ribosome distorts ribosomal conformation. 
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Chapter 1 Introduction  
 
 
 
The transfer of information from DNA to RNA then to protein is regarded as the central 
dogma of molecular biology (Crick et al., 1970). This procedure, however, is not a 
linear, simple one, instead, it is a complicated course of many events, in which great 
number of factors are involved. In eukaryotic cells, RNA is transcribed by three 
polymerases: RNA polymerase I and III, which transcribe the RNAs that will not be 
further decoded for proteins (non-coding RNA), such as rRNAs forming the RNA 
section of ribosome, or tRNA involved in translation and RNA polymerase II, which 
mainly transcribes the mRNA precursor that encode proteins (Dieci et al., 2007; Sims et 
al., 2004; Russell et al., 2006). The precursor mRNA is not used in translation directly, 
it has to be processed by several modifications before translation. The main 
modifications are addition of 5’ 7-methyl-guanosine cap and 3’ poly-A tail, which are 
critical for translation and also protect the mRNA from nucleases, and RNA splicing 
that removes the introns from the pre-mRNA (Cogoni et al., 2000; Helm et al., 2006).  
 
Mature mRNA directs the ribosome to synthesise the peptide chain corresponding to its 
nucleotide sequence. Occasionally, however, the outcome of protein synthesis does not 
match that predicted from inspection of the mRNA sequence. Such phenomena are 
termed as translational recoding events. Most translational recoding events are driven by 
features of the mRNA, such as stem loops or pseudoknots adjacent to the recoding site. 
These are, though, recoding events directed by the amino acid sequence of the nascent 
chain. The 2A reaction, analysed in this thesis, falls within this category.  
 
The 2A reaction is directed by a collection of short peptides (20~30 amino acids long) 
termed 2A peptides. During the translation, they cause a ‘skip’ in peptide bond 
formation at the C-terminus of their sequences, which results the generation of two 
polypeptides from one open reading frame, an extremely unusual event during 
 2 
translation. The 2A reaction was initially found during the study of foot and mouse 
disease virus, a picornavirus that infects cloven-hoofed animals. While playing critical 
roles in the life-cycle and reproduction of many picornavirus as well as a number of 
other viruses, 2A peptides are also found in the genome of other organisms, such as 
cellular genes of sea urchin and non-LTR retrotransposons in a wide range of both 
unicellular and multicellular organisms (Heras et al., (2006) and M. Ryan personal 
communication). Interestingly, 2A peptides only promote the 2A reaction in concert 
with the eukaryotic translational apparatus. 
 
In the introduction of this thesis, procedure of the ‘textbook’ model of protein 
translation are described, for offering the background information of 2A reaction; 
(section 1.1) followed by a summary of different types of translational recording events 
as well as other unconventional translational mechanisms that are relative to 2A (section 
1.2). The final part (section 1.3) of this chapter summarizes the previous research on 2A 
reaction and 2A peptides. 
 
1.1 Translation and the ribosome 
 
Protein synthesis, the biogenesis of protein with mRNA as template is a sequential and 
precise procedure, with numerous biological macromolecules involved. The ribosome, 
the platform where translation occurs, is the centre of the translational apparatus. 
   
 
1.1.1 Structure and function of the ribosome 
 
The ribosome, is a large ribonucleoprotein particle, and in all species comprises two 
subunits. In eukaryotes, the subunits are designated 60S and 40S, and together make up 
80S ribosome complex. The 40S subunit is composed of one RNA component (18S 
rRNA) and 33 ribosomal proteins (rprotein) whereas the 60S subunit has 3 rRNA (5S, 
28S and 5.8S respectively) and 46 rproteins (Ben-Shem et al., 2011; Klinge et al., 2011; 
Rabl et al., 2010). The core structure of ribosome from all species is universally 
 3 
conserved, and the rRNA sequences beyond the core structure, that are different 
between eukaryotic, prokaryotic and archaebacterial ribosomes, are termed expansion 
segments.  During translation, the small subunit directs amino acyl-tRNAs to read the 
mRNA sequence, and the large subunit hosts tRNA and catalyzes the formation of the 
peptide bond. On the interface between two subunits, there are three tRNA binding sites, 
formed by ribosomal RNA. The tRNA-binding sites are: the aminoacyl site (A site) 
decoding the mRNA through the codon-anticodon base pairing, and working as the dock 
of the ribosome for the incoming amnoacyl tRNA; peptidy site (P site), holding the 
tRNA with the growing peptide chain (peptidyl-tRNA); and exit site (E site), the site 
from which the deacylated, uncharged tRNA leaves ribosome (Kim et al., 1999; Berk et 
al., 2006). The principal chemical reaction of protein synthesis, peptide bond formation, 
is carried out by the peptidyl transferase centre (PTC), a region of large subunit that is 
adjacent to the P and A sites. During translation, it catalyzes bond formation between 
the amino acids of aminoacyl tRNA in A site, and the nascent peptide chain of 
peptidyl-tRNA in P site, with assistance of several elongation factors (Figure 1.1) 
(Beringer et al., 2007; Polacek et al., 2005). This function, is not mediated by rprotein, 
but by rRNA (in eukaryotic ribosome by 28S rRNA of the large unit) (Noller et al., 
1993; Simonovic et al., 2009). 
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Figure 1.1 Schematic of peptide bone formation on ribosome, adapted from Beringer et 
al., (2007). 
 
 
Extending from the PTC, there is a long aqueous tunnel through the large subunit 
named the ribosomal exit tunnel, where the growing nascent chain is temporally hosted 
and, after release from peptidy-tRNA, emerges to the cytoplasm (Yonath et al., 1987; 
Milligan et al., 1986). The exit tunnel is 100 Å long from PTC to the outside surface of 
the ribosome, and 15 Å in average diameter; in a roughly cylindrical shape, though 
 5 
highly irregular in detail (Nissen et al., 2000) (Figure 1.2). The wall of the tunnel is 
mainly composed of rRNA components, but also includes regions of several ribosomal 
proteins which are unconserved between eukaryotic and bacterial ribosome. When first 
discovered in the mid-1980s, the ribosomal exit tunnel was considered as a rigid, 
passive tunnel. However, over the years, a considerable body of evidence has 
accumulated that is consistent with it being active during translation and that the exit 
tunnel participates in a range of co-translational events, such as crosstalk to the residues 
of the nascent chains or co-translational process of proteins (Ito et al., 2013; Ziv et al., 
2005; Yap et al., 2009). The rproteins harboured inside the tunnel are indicted to be 
involved in these events (Ito et al., 2013). As 2A peptides only function with the 
eukaryotic translational system, the difference of rprotein components between the 
eukaryotic and bacterial ribosome might be considered one of the factors that drive this 
specificity, and candidates for studies that might lead to insight into its mechanism. 
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Figure 1.2 Schematic of the finding of cryo-EM of prokaryotic and eukaryotic 
ribosomal exit tunnels, with respective stalling peptides, TnaC (blue) and uORF2 (green) 
emerging from the ribosome. The residues of rRNA and rprotein are represented by 
azure and other colorful shapes respectively. Specifically, the azure curve H50 stands 
for the important rRNA Halices H50. Taken from Bhushan et al., (2010).   
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1.1.2  ‘Text-book’ protein synthesis 
 
Protein synthesis, the biogenesis of protein with mRNA as template in the ribosome, is a 
sequential and precise procedure, with several translation factors involved (for review 
see Schmeing et al., 2009 and Rodnina et al., 2009). 
 
 
1.1.2.1 eukaryotic mRNA 
 
The mRNA is the substrate of translation. In eukaryotic organisms, the basic structure of 
mRNA typically comprises 5 parts: a 5’ 7-methyl-guanosine cap structure (m7G-cap), a 
5’ untranslated region (UTR), the coding region to be translated, followed by a 3’ UTR 
and a poly(A) tail in  the 3’ end (Cogoni et al., 2000; Helm et al., 2006; Moore et al., 
2005). 
 
The 3’ and 5’ UTR may contain secondary structure like hairpin structure or internal 
ribosome entry site, which are often found to regulate translational efficiency or protein 
localization (Cenik et al., 2011). The m7 cap and poly (A) tail are necessary for the 
initiation of translation, as m7G cap offers the binding site of 43S pre-initiation complex, 
(see below) while poly(A) tail recruits poly (A) binding protein (PABP) that enhance the 
association between 43S complex and m7G cap structure. The coding region, or open 
reading frame (ORF), starts with the first methionine codon (AUG, termed as start 
codon) of the mRNA transcript, and ends with the one of three stop codons (UAA, UAG, 
UGA), with the ORF being decoded into a single protein chain (Acker et al., 2008; 
Rodnina et al., 2009). 
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1.1.2.2  Eukaryotic translational process 
 
There are three major steps in translation: initiation, elongation and termination.  
 
 
 1.1.2.2.1 Initiation 
 
The first and rate-limiting step in translation is initiation. Initiation entails two stages. 
During the first stage, eukaryotic initiation factors eIF3, eIF1A, eIF1 and eIF2 
associated with initiator Met-tRNA and GTP, join the ribosomal 40S subunit, to form 
the pre-initiation 43S complex; on the other hand, eIF4E, eIF4A, eIF4G, the eIF4F 
complex, binds mRNA at its 5’ m7 cap structure to facilitate the binding of the 43S 
complex to the mRNA. As the association of the 43S complex with mRNA relies on 5’ 
m7 cap structure, this kind of mRNA recruitment is termed the 5’end dependent 
pathway. During the second stage of initiation, the 43S complex associates with the 
mRNA at its 5’ terminus. It then moves on mRNA in 5’ to 3’ direction, ‘scanning’ for 
the initiation codon. On recognition of the initiation codon of mRNA, initiation factors 
release and ribosomal 60S subunit joins to the 40S subunit, forming the whole 80S 
ribosome; meanwhile the initiator Met-tRNA lands in the P-site of the ribosome, 
decoding the initiation codon and completing the initiation. There are three major 
differences between eukaryotic and prokaryotic initiation: firstly in prokaryotes the 
mRNA recruitment is 5’end independent, the association of pre-initiation complex and 
mRNA is mediated by the sequence of mRNA  (termed Shine-Dalgarno)  rather than 
mRNA binding factors; secondarily, the pre-initiation complex in prokaryotes binds 
directly, not slides to, the start codon, which is adjacent to the Shine-Dalgarno sequence 
of mRNA; thirdly, the fMet-tRNA, the initiator in prokaryotes, joins the pre-initiation 
complex after the complex binding to the mRNA (Amrani et al., 2008; Acker et al., 
2008; Rodnina et al., 2009; Jackson et al., 2010). 
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1.1.2.2.2 Elongation  
 
 The second step of tranlation is elongation, the process of decoding the mRNA and 
extending the peptide chain. The basic cycle of elongation includes 3 processes. 
  
In first process, a ternary complex comprising a eukaryotic elongation factor eEF1A, 
GTP and an aminoacyl-tRNA, enters the ribosome. This leads to a series conformational 
changes of the ribosome and induces the hydrolysis of the GTP by eEF1, and further 
results in the delivery of the cognate aminoacyl-tRNA to the A-site to decode the codon 
residing in the site. This codon recognition (decoding) is the key step of elongation, and 
one of the main translational progress that 2A changes. Therefore, in this introduction, a 
skeleton of the pathway of the decoding mechanism is offered. Due to the lack of detail 
on the decoding of eukaryotic system, this summary on decoding is based on studies 
carried out in bacteria. But because the elongation mechanism is considered highly 
conserved between prokaryotic and eukaryotic translation, the eukaryotic decoding 
presumably follows the same pathway as the prokaryote described below, albeit the 
decoding appears to take place somewhat more slowly and accurately in higher 
eukaryotes (Ito et al., 2013; Voorhees et al., 2013). 
 
 
In bacteria, the ternary complex (in which the eEF1A replaced by EF-Tu, the bacterial 
homolog of eEF1A, that is also a GTPase) enters the ribosome, and the anticodon helix 
of the tRNA of the complex is delivered to the A site of ribosome, with assistance of 
rprotein L7/L12. In the A site, the tRNA anticodon and codon mRNA sequence pair to 
each others. During the pairing, three universal conserved residues of rRNA (in bacterial 
there are A1492, A1493, and G530 of 16S rRNA) interact with the minor groove of the 
cognate condon-anticodon helix at the first and second but not third positions, this 
monitors the correct base-pairing, The ‘cognate-specific’ binding energy generated from 
the these interactions is used to three events: (i) to increase the relative affinity of 
cognate tRNA (ii) to induce the large scale rearrangement of domains of small subunit 
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(closure conformation), which increases the fidelity of the translation; and (iii) to induce 
the conformational changes on the ternary complex, triggering the GTP hydrolysis by 
the EF-Tu, that further causes the release of the EF-Tu from the ribosome (Rodnina et 
al., 2005; Ogle et al., 2005). The hydrolysis of GTP also induces a proofreading step 
after the initial selection. As the conserved rRNA only monitors the first two pairs if the 
nucleotides of codon-anitcodon pairing, a fraction of tRNA with one mismatch to the 
codon at the A site remains in the initial selection. Some of the non-Watson-Crick base 
pairings are allowed in the decoding (wobble site of the genetic code at third position of 
the codon), but certain tRNAs with one mismatch (near cognate tRNA) are rejected in 
proofreading step, where whether the acceptor end of a tRNA is accommodated to the 
PTC is determined. The mechanism of proofreading remains largely unknown, but 
evidence suggests that it is a complex process involving the rRNA and rprotein of both 
ribosomal subunits and conformational rearrangement (Jenner et al., 2010; Demeshkina 
et al., 2012). 
 .  
After the accommodation of the aminoacyl-tRNA comes the second process of 
elongation. The ribosomal peptidyl-transferase centre catalyses the formation of a 
peptide bond between the aminoacyl-tRNA in A site and peptidyl-tRNA (synthesized in 
previous elongation cycle) in the P-site, leaving the tRNA in P-site deacylated (see 
Figure 1.1) (Beringer et al., 2007). 
 
The third and final process of elongation is translocation: after peptide bond formation, 
another elongation factor eEF2, a GTPase, enters the ribosome with a GTP, and 
catalyzes the GTP hydrolysis there. With the energy released from the hydrolysis, the 
ribosome translocates 3 nucleotides toward 3’ end of mRNA, moving the peptidyl-tRNA 
in A site and deacylated tRNA in P site to the P site and E site respectively. Therefore, 
the A site is emptied, ready for the next elongation cycle (Taylor et al., 2007). 
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1.1.2.2.3 Termination  
 
The third and last step of translation is termination, in which the ribosome arrives the 
one of three stop codons (UGA, UAG, UAA) that ends the open reading frame in the 
mRNA and the nascent polypeptide is released. In eukaryotic translation, two eukaryotic 
release factors are required for termination: eRF1 and eRF3. These two factors enter the 
ribosome in a state of complex (Pisareva et al., 2006). 
 
Unlike the prokaryotic release factors that use different factor to decode different stop 
condon, the eukaryote recognizes all three stop codons with eRF1 only. Studies have 
revealed that the conserved motifs of the N-terminal portion (domain 1) of the eRF1, 
such as NIKS-loop or YxCxxF motif, play the centre role of stop codon recognition. 
The concomitant amino acid replacement(s) on these motifs may cause the impairment 
on the efficiency of the recognition, or produce the ‘UGA only’ eRF1 mutants that can 
only decode stop condon UGA. These findings suggest that the eRF1 N-domain 
recognize stop codon through complicated three dimensional network formed by its 
conserved resides (Chavatte et al., 2002; Frolova et al., 2002; Seit-Nebi et al., 2002; 
Kolosov et al., 2005; Cheng et al., 2009). 
     
The eRF1 is very versatile during termination. Except its N-terminal portion that 
recognizes all three stop condons, it also contacts several key nucleotides of 
peptidy-transferase centre with the conserved GGQ motif in its domain 2. This realizes 
the second major function of the factor, triggering the release of nascent chain from 
peptidyl–tRNA.  
 
The eRF3, a GTPase, binds to eRF1 in high affinity with the domain 3 of the latter 
(Kolosov et al., 2005; Cheng et al., 2009). Studies suggest, the hydrolysis of GTP 
catalyzed by eRF3, induces the conformational rearrangement of eRF1, resulting the 
couple of two major functions of eRF1: stop codons recognition and catalysis of peptide 
relaease (Alkalaeva et al., 2006). 
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Although the eRF1 and eRF3 plays the central role of the translational termination, 
recent studies have revealed the involvement of other factors. For example, the 
iron-sulphur protein RNase L inhibitor (Rli1) was reported associated physically with 
eRF1 during termination, and regulation of the Rli1 affected the efficiency and accuracy 
of the latter with a positive related manner (Khoshnevis et al., 2010). Besides, the Rli1 
was also found collaborating with released factors to slip the ribosomes into their 
subunits after the release of the nascent chain, thus trigging the recycle of the 
translational components (Pisareva et al., 2010).     
 
 
1.2 Unconventional translational mechanism 
 
Section 1.1 describes the course of standard ‘textbook’ translation. But the progress of 
protein synthesis is not always as simple as this description. Occasionally the outcomes 
of translation do not match those predicted from inspection of mRNA sequences, and 
these events are termed ‘translational recoding events’. In other cases, the efficiency and 
output of translation, can be co-translationally controlled by regulatory factors, with the 
approach of pausing or stalling the course of translation. As mentioned above, these 
unconventional events are driven by either the template mRNA or product nascent 
peptide chain.  
 
As 2A reaction, the topic of this project, is a translational recoding event, and directed 
by the peptide sequence, this section reviews several unconventional events, to look for 
the insights for understanding the 2A mechanism.  
 
 
1.2.1 Internal Ribosome Entry Sites (IRES)  
 
 
As mentioned in section 1.1.2, in the typical eukaryotic initiation, recruitment of the 
mRNA is via 5’-end cap dependent pathway. In some cases, however, the structure of 
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RNA is able to recruit the ribosomal subunits directly and initiate translation in a 5’-end 
independent manner. Such RNA structures are collectively termed internal ribosome 
entry sites (IRESs). IRESs were firstly found in virus study, but later also in eukaryotic 
cellular mRNA. As of 2009, there are 68 viruses and 115 eukaryotic mRNA reported to 
contain IRES (www.iresite.org). IRESs in different organism varies in biological role. 
For eukaryotes, IRES dependent initiations are active during cellular stress, mitosis or 
apoptosis conditions, where the canonical factors that typical initiation needs 
compromised or impeded. This suggests cellular IRESs are developed to deal with the 
transient stress (Holcik et al., 2000; Stoneley et al., 2000; Lang et al., 2002). The IRESs 
of virus, on other hand, are suggested playing a role of regulatory element. Under the 
infection condition, the canonical initiation is prevented by the virus with proteolysis of 
initiation factors, or host cell, with regulation. In such condition, the virus needs 
IRESs-induced initiation to start the translation of viral proteins. Studies of IRES 
suggest that there is no universal mechanism of IRES. In terms of origins, mechanism 
and sequence similarity, the reported viral IRESs can be classified into 4 types. Each 
type requires unique subset of initiation factors and cellular proteins that have no known 
relatives with translation (Redondo et al., 2012; Yu et al., 2000). However, one unifying 
feature is that all these mechanisms include the unconventional interaction between the 
mRNA structure of IRES and normal translational apparatus (Jackson et al., 2013). 
 
 
1.2.2 Ribosomal frameshifting 
 
One of the most important functions of the ribosome is to maintain the reading frame. 
However, in specific situations ribosomes are prompted to move into a different reading 
frame (both forward, marked +, or backward marked -), to produce different proteins 
from the same transcript. 
 
Ribosomal frameshifting occurs in many situations. For example, many retroviruses use 
this mechanism to produce Pol protein (frameshifting -1) as a fusion to their Gag 
protein (Brierley et al., 2006; Dos Ramos et al., 2003). In bacteria and eukaryotes, the 
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expression of type II release factor (RF2), and ornithine decarboxylase antiyme are 
mediated by +1 frameshifting respectively (Craigen et al., 1987; Ivanov et al., 2004).  
 
 
The typical elements of mRNA that induce frameshifting are two sequences: the first is 
a so-called slippery sequence that constitutes the shifting site. In such a sequence, 
frame-shifting does not affect the condon-anticondon pairs of tRNA with mRNA in the 
P and A site of the ribosome. For example, the shifting site of Gag-Pol gene of HIV-1 is 
UUUUUUA, before the shifting the sequence is read as UUU UUU A, and after shifting, 
U UUU UUA. In both frames Phe-tRNA is able to pair with the codon in the P and A 
sites cognate to, or form a wobble site (see section 1.1.2.2.2) with the mRNA sequence 
(Mouzakis et al., 2013). The second element is the secondary structure of the sequence 
downstream to the shifting site, usually a pseudoknot, a nucleic acid secondary 
structure containing at least two stem-loop structures in which half of one stem is 
intercalated between the two halves of another (Giedroc et al., 2009; Brierley et al., 
1989). It is general believed, that the frameshifting is achieved by the cis coupling of the 
slippery sequence and structured mRNA. The current model to explain the frameshifting 
mechanism (Dinman et al., 2012) comprises 2 major steps: firstly, while the slippery 
sequence arrive to the P and A site of ribosome, the ribosome was paused by the 
resistance of the downstream structure; and secondly, a fraction of ribosomes slip 1 
nucleotide to 5’ or 3’-direction, but the exact point of this slip has not been identified 
yet (Giedroc et al., 2009; Brakier-Gingras et al., 2012; Plant et al., 2003; Liao et al., 
2012). A recent cryo-EM study generated data consistent with a mechanical explanation 
for how a pseudoknot in the RNA can cause a -1 frameshift. In this study, the slippery 
sequence was replaced with a non-slippery sequence. The structure of ribosomes 
translating an mRNA containing this modified RNA suggested that the pseudoknot 
became wedged into the ribosomes, causing them to stall, unable to complete the 
translocation step in the elongation cycle. It was inferred from this that in the presence 
of the slippery sequence, the tension within this complex could be released by the -1 
frameshift on the mRNA (Namy et al., 2006). 
 
 15 
 
 
 
 
 
 
 
1.2.3 Stop codon readthrough 
 
Translation termination occurs when one of three stop condon occupies the A site of 
ribosome. However, a growing number of events have been identified where tRNAs 
(termed suppressor tRNA) are able to decode the stop codon (nonsense condon), 
allowing translation to proceed downstream. Such events are together termed 
‘programmed stop codon readthrough’. As during the readthrough event, there still are a 
fraction of ribosomes terminating the translation at the stop codon, the event lead to 
production of 2 proteins: the product that released at the stop codon (termination 
product), and the readthrough product, from the single transcript. Many viruses employ 
this mechanism, and an example is the RNA phage Qβ infecting E. coli. During the 
translation of the end of Q-coat protein, a fraction of ribosomes incorporate tryptophan 
instead of terminating translation at a UAG stop codon, resulting a elongated coat 
protein that is critical for its infection (Hofstetter et al., 1974); a second example is the 
murine leukemia virus, (MuLV) that generates its Gag-Pol precursor, by decoding its 
UAG termination condon with tRNA
Glu
 (Yoshinaka et al., 1985; Yoshinaka et al., 
1985(2); Brierley et al., 2007). Though the majority of readthroughs identified are in 
viral genes, there are several cellular genes employing the mechanism. For example, 
Drosophia uses readthrough to regulate the ratio of two proteins, Hdc and the long Hdc 
protein, during development (Steneberg et al., 2001). 
 
The 3’- adjacent nucleotides to the stop codon are believed to be important for 
readthrough. Taking into account to the requirements of the mRNA sequence and/or 
structure stimulating the event, readthrough occurring in eukaryotic system can be 
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classified into three types: type I, with a stimulatory motif ‘UAG-CAA-UYA’; type II, 
the three nucleotides 3’-ajacent to the stop codon UGA are either CGG or CUA; and 
type III (represented by MuLV mentioned above), in which the high-level of  
readthrough requires the secondary structure of mRNA several nucleotides downstream 
from the stop codon (Brierley et al., 2007; Beier et al., 2001; Harrell et al., 2002). 
However, some recent studies point out, in the first two type of readthrough, 
downstream structured mRNA is more generally involved in the events than previously 
thought, and several cases of readthrough are reported relying both 3’- adjacent 
nucleotides and the secondary structure of downstream mRNA (Napthine et al., 2012; 
Firth et al., 2011). 
 
 
 
1.2.4 Ribosomal stalling peptides 
 
As mentioned in section 1.1.1, the ribosomal exit tunnel plays an active role in the 
biogenesis of proteins. The interaction between nascent peptide chain and components 
of exit tunnel is perhaps is a frequent occurrence. In some cases, this kind of contact 
induces conformational changes to the ribosome and/or the positioning of the nascent 
chain, and results in stalling of translation, with specific codons in the PTC. 
Peptide-induced translational stalling in different origins is evolved independently and 
carries out distinct affects (Ito et al., 2013; Yan et al., 2010). They are not translational 
recoding, but since the 2A reaction includes a translational pause (see section 1.3), it is 
an important aspect to translation to discuss here. This section offers an introduction to 
four typical ribosomal arresting peptides (RAP), and a more comprehensive list of 
known RAPs is provided in Table 1.1.    
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Table 1.1 Main translational arresting peptides, their organism, arresting sequence 
(motif highlighted with red colour) and inhibition point. Taken from Ito et al., (2013). 
 
 
 
1.2.4.1 secM   
 
Secretion monitor (secM) lies upstream to, and regulates the expression of secA gene, 
encoding SecA, a key component of protein secretion apparatus of E. coli. I SecM has 
both an N-terminal signal sequence, and a sequence (FxxxxWIxxxxGIRAGP) that 
causes ribosomes to stall. This in turn disrupts the secondary structure of the secM-secA 
mRNA, which, interestingly, leads the entry of new ribosome that translates secA, and 
finally results the upgrade of SecA expression (Nakatogawa et al., 2001). Efficient 
engagement of nascent SecM with the export machinery counteracts the effect of the 
stalling peptide, and translation efficiency of SecA is lowered. This provides a 
regulation of SecA (which encodes an ATPase that drives export through the secYEG 
translocon) synthesis in response to translocation efficiency. 
 
The short peptide SecM (F
150
xxxxWIxxxxGIRAGP
166
) directing the ribosomal arrest is 
from amino acids 150 to 166 of the 170-amino-acid polypeptide. During the stall, the 
codons of Pro166 and Gly165 are positioned in the A and P sites respectively, and 
Prolyl-tRNA also lands in the A site. However, the ribosomal peptidyl-transferase fails 
to form the peptide bond between Prolyl-tRNA and peptidyl-tRNA in P site 
(Nakatogawa et al., 2002; Muto et al., 2006; Garza-Sanchez et al., 2006).  
 
 
Insertion of fluorescent probes into the SecM peptides allowed FRET (fluorescence 
resonance energy transfer) studies to be carried out on the stalled SecM-ribosome 
complex, and the data collected reveal that during the reaction, all the 17 amino acids of 
the motif rest in the exit tunnel, in a compact, perhaps helical form, and mutagenesis on 
the ribosomal components that consistent the narrowest region of the exit tunnel, both 
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of rprotein (L22) and rRNA, (23S rRNA) compromise the SecM-induced stalling 
significantly. These facts strongly suggest the existence of interactions between the 
SecM nascent chain, and the exit tunnel component (Nakatogawa et al., 2002; 
Woolhead et al., 2006). Cryo-electron microscope studies reveal the distinct 
rearrangement to the ribosome structure and peptidyl-transferase centre, which is 
potentially the result of such interactions (Mitra et al., 2006; Bhushan et al., 2011).  
 
The SecM motif (F
150
xxxxWIxxxxGIRAGP
166
) composed of nine amino acids was 
isolated by alanine-scanning mutagenesis (Nakatogawa et al., 2002). However, a further 
mutagenesis study revealed that, besides the G-P pair at the C-terminal end, only 
arginine at position 163 is indispensable for the full function of SecM, and the 
mutations at other key amino acids could be compensated by re-modeling of other 
positions. This finding suggests while the Arg163 appears to play singular function in 
translational stalling, the other residues between 150 and 165 that play a “secondary” 
role probably fall into at least one other functional class (Yap et al., 2009). Considering 
the research discussed above that suggests the interaction between nascent chain and 
ribosomal component, a possible explanation is that, all residues located at 150~166 
except Arg163, by forming a certain conformation or interaction with the exit tunnel, 
correctly position Arg163 into a precise intra tunnel site where it is able to contact 
critical component hence further trigger the ribosome stall, with the G-P pair of the 
peptide at the decoding site. This explanation was a consistent with the cryo-EM study 
on the peptides, which offered critical evidence that R163 contacted with A2603 of 
ribosome (Bhushan et al., 2011).          
 
Proline at the A site itself is poorest electrophile for peptide bond formation (Nathans et 
al., 1963) and reaction involving it are then perhaps more likely to be sensitive to the 
perturbation of ribosomal geometry than other amino acid. The spatial stack of its 
unique proline ring structure also means that it is less flexible to accommodate the 
subtle ribosomal rearrangement. The glycine at the P site is also poor electrophile 
(Nathans et al., 1963), making G-P one of the worst couples in term of making the 
peptide bond (Rychlík et al., 1970). This situation, plus the ribosomal conformational 
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change potentially caused by the nascent chain-ribosomal exit tunnel contact, might be 
the reason that peptidyl-transferase fails to form the peptide bond between the final 
Prolyl-tRNA and peptidyl-tRNA in P site (Yap et al., 2009). 
 
 
1.2.4.2  TnaC 
 
The leader peptide of the tryptophanase operon of E. coli, TnaC, is a 24 amino acids 
long peptide. It responds to high concentrations of tryptophan, upregulating the 
expression of downstream genes whose function is catabolism of tryptophan, with a 
delicate mechanism starting with a ribosome arrest (Gong et al., 2001; Gong et al., 
2002). 
 
At the point that the ribosome is stalled by the peptide, the P and A sites are occupied by 
the final proline codon (Pro24) of the peptide open reading frame, and the stop codon in 
the end of the ORF respectively. However, termination at the stop codon in A site does 
not occur, thus, the ribosome is arrested by TnaC peptide at its own stop codon. 
Mutagenesis studies have highlighted key residues of TnaC, they are Trp12, Asp19 and 
final proline in the 24th position (Cruz-Vera et al., 2008). Similar to SecM, mutations in 
components of the ribosomal exit tunnel constriction suppress TnaC-induced stalling. 
Like SecM, this again agrees with the contact of nascent chain and exit tunnel 
(Cruz-Vera et al., 2005). The possible result of these contacts is revealed by a recent 
cryo-EM research, that indicates in the arrested ribosome, two conserved nucleotides of 
PTC adopt conformation that precludes release factor binding (Seidelt et al., 2009). 
These findings/data explain the failure of translation termination at the TnaC stop 
codon. 
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1.2.4.3  Cytomegalovirus UL4 uORF2 
 
The ribosome arrested peptides reviewed in last two sections are functional in bacterial 
translational apparatus. Similar phenomena have been observed in eukaryotes. UL4 
uORF2 of cytomegalovirus, a virus infecting human, is a case in point (Cao et al., 1996). 
The UL4 coding region is present on a transcript containing three upstream open 
reading frames (uORF). The second one (uORF2), a 22 amino acid long leader peptide, 
suppresses translation of the downstream main open reading frame with a mechanism 
that, like TnaC, is due to pausing of ribosomes with the stop codon of the uORF in the 
ribosomal A site. This results in a persistent covalent attachment between the nascent 
chain and the final tRNA, which, also similar to TnaC, is proline (Cao et al., 1996; Cao 
et al., 1995). 
 
Unlike TnaC that precludes the release factors from ribosome by altering ribosomal 
conformation, during the uORF2-induced ribosome stalling, eRF1 (but not eRF3) is 
recruited to the ribosome, and mutations in GGQ motif of eRF1 significantly impair the 
duration of the stall. This finding suggests the release factor eRF1, particularly the 
domain 2 that catalyze the hydrolysis of nascent chain in canonical translation, play a 
critical role in the arrest. Furthermore, the final two prolines of uORF2 are required for 
the stalling (Janzen et al., 2002). To explain these data, a model was proposed that, the 
carboxy terminal proline residues, and the GGQ motif of eRF1 contacted each other to 
stabilize an intermediate in termination, while the potential interaction(s) of ribosomal 
component and the rest of nascent peptide altered the geometry of ribosomal PTC 
and/or shift the position of uORF2-tRNA, to enable such contacts (Figure 1.3) (Janzen 
et al., 2002). 
 
This model was partly supported by a recent cryo-EM study, which showed direct 
interactions of the nascent chain and the components of exit tunnel (rprotein L4 and 
L17), and significant changes at the PTC: the eukaryotic-specific rprotein L10e 
contacted uORF2-tRNA at its CCA end (Bhushan et al., 2010). But more details of this 
type of termination arrest will undoubtedly emerge from further analysis.  
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Figure 1.3 Model of uORF2 induced termination inhibition, taken from Janzen et al., 
(2002). The altered PTC allows the GGQ motif of eRF1 contacting with final prolines 
of the peptide, stabilize an intermediate in termination.  
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1.2.4.4  Arginine attenuator peptide (AAP) 
 
Another typical ribosomal arresting peptide working with eukaryotes is arginine 
attenuator peptide. During their translation, a variety of fungal species including S. 
cerevisiae and N. crassa use AAP uORF arresting the ribosome, to restrict translation of 
a component of arginine biosynthetic pathway downstream, in response to high arginine 
level (Fang et al., 2000). 
 
Like UL4 uORF and TnaC described above, AAP arrests the ribosome with its stop 
codon in the A site, but the final amino acid condon that is in P site during the stall, is 
not a conserved position of the peptide. Therefore, the motif of AAP is in the ‘middle’ of 
the peptide, with non-conserved amino acids forming its N- and C-terminal portion. 
Most intriguingly, the stop codon in the end has been proved unnecessary for its ability 
to stall ribosome: replace it with a sense condon, ribosome stall at several positions just 
downstream to the AAP. The mechanism of AAP-induced ribosome stalling remains 
unknown, but according its unique features, it would appear to be very distinct from 
other three peptides introduced in this section (Fang et al., 2004; Wang et al., 1997). 
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1.3 2A sequences and the 2A reaction 
 
 
 
A focus of research in the Brown laboratory for the past few years has been short 
peptides, collectively known as 2A peptides, and also termed ‘CHYSELs’ (cis-acting 
hydrolase elements) (de Felipe et al., 2004) that both pause ribosomes and dictate a 
translational recoding mechanism: They cause a co-translational ‘skip’ in peptide bond 
formation at their C-terminus (Doronina et al., 2008). This results in separation of the 
polypeptide containing the 2A sequence, into two parts: the product containing the 
sequence upstream to and including most of 2A, (upstream product) and product 
downstream to and including the final proline of the peptide (Downstream product). The 
activity of 2A sequences is only dependent on the peptide sequence, not RNA sequence 
(Ryan et al., 1994).    
 
2A peptides have been found in a number of viruses, where they play important roles in 
their life-cycle and reproduction, as well as cellular genes of sea urchin (M. Ryan 
personal communication) and in Trypanosomal repeat sequence (Heras et al., 2006; 
Oden et al., 2013). Typically, the 2A peptide has length of ~20 amino acids. The 
sequences can be divided into two parts: an N-terminal non-conserved sequence which 
in some 2As has a strong α-helical propensity, followed by a conserved motif 
D(V/I)EXNPGP. The separation of the nascent chain is at the C-terminal end of the 
conserved motif, between glycine and proline (Figure 1.4).  
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Figure 1.4 2A peptides: The alignment of 2A-like peptides sequence from different 
species shows a conserved motif D(V/I)EXNPGP at C-terminus. Data collected from 
http://www.st-andrews.ac.uk/ryanlab/Index.htm 
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1.3.1 The 2A reaction is a co-translational event rather than a proteolytic cleavage 
 
 
 
   The first 2A peptide identified and the most extensively studied so far is the 2A 
peptide of the aphthovirus foot-and-mouth disease virus (FMDV). The studies on 2A 
peptide can be traced back to the work of Ryan and his colleagues in 1991 (Ryan et al., 
1991). In that research, it was found that a 19 amino acide long short peptide spanning 
the 2A region of the foot-and-mouth disease virus polyprotein, was responsible for a 
‘primary proteolytic processing’ event occuring between the 2A and 2B regions of the 
polyprotein. Initially it was thought that the separation of the polypeptide chain was 
carried out post-translationally and that ‘either an unidentified virus-encoded proteinase 
may be responsible, or that 2A acts as a substrate for a host cell proteinase’, as 2A 
protein of many other viruses is a protease. However, in follow-up work (Ryan et al., 
1994) this hypothesis was discounted.  
 
  Key observations in (Ryan et al., 1994) were made with an artificial polyprotein 
system (plasmid pCAT-2A-GUS), in which the 19 amino acid 2A peptide from FDMV 
was inserted between two reporter protein, chloramphenicol acetyl-transferase (CAT) 
and β-glucuronidase (GUS).  In the in vitro translation experiment with the rabbit 
reticulocyte lysate system, high-level of CAT-2A (upstream product) and GUS 
(downstream product) was observed, as well as a small amount of full-length product 
(CAT-2A-GUS). This means existence of the high-level 2A-mediated ‘cleavage’ activity. 
Given the 2A peptide is the only component in the experiment from FMDV, this result 
discounted the possibility that virus-encoded proteinase participated in the 2A reaction. 
Another important result within this work, kinetic analysis, showed that the full-length 
product was stable, arguing against the involvement of host cell proteinase in a 
post-translational cleavage of the protein. Therefore, the suggestion that a co-translation 
event resulted in ‘cleavage’ of the protein was suggested for first time (Ryan et al., 
1994). 
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Further evidence in favour of the co-translational model of 2A reaction was a molar 
imbalance of the up- and down-stream products, with a greater amount of upstream 
product being made than downstream seen in some experiments. This was observed 
with several independent fusions containing the FMDV 2A peptide.  As this imbalance 
could not be explained by protein degradation or premature termination of transcription 
or translation, the only possibility was that it was due to the differential rates of 
synthesis of the two products, for example, the ribosome might fall off from mRNA 
after generation of upstream production. Therefore, the 2A-mediated cleavage is 
strongly suggested as a novel translational event within ribosome, rather than 
proteolytic reaction after translation (Donnelly et al., 2001a; Donnelly et al., 2001b). 
 
More recent and decisive evidence confirming the 2A reaction as a co-translational 
event has come from study in Dr. Brown’s laboratory (Doronina et al., 2008). In this 
study, it was found that, with truncated transcripts only extending to the Pro19 of 2A 
(without stop codon), the 2A reaction still occurred, the peptide driving the ribosome to 
release the upstream product. This result demonstrated conclusively the co-translational 
nature of the 2A reaction, and that the reaction takes place in PTC of the ribosome. 
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1.3.2 Features of 2A reaction 
 
During investigation into the primary mechanism of the 2A reaction, many other 
faces of it were discovered. In the study of Donnelly et al., 1997, it  was found that the 
upstream context of 2A in FMDV, although not crucial for 2A reaction, played a 
important role, as insertion of upstream FMDV capsid protein 1 D sequences (which 
preceed 2A in the virus) upstream of 2A increased activity. The same study also 
discovered that, while the 2A functions in a variety of eukaryotic translation systems, it 
was not active when translated by prokaryotic ribosomes. 
 
 
 
1.3.3 Beyond FMDV 2A 
 
 
While the co-translational mechanism of the FMDV 2A reaction was being 
uncovered, many other examples of ‘2A-like’ short peptides had been found and the 
common features of these peptides had been noted. Donnelly et al., 1997 found that the 
homologues of 2A in other members of family picornaviridae, namely Theiler's murine 
encephalomyelitis virus (TME) 2A protein and encephalomyocarditis virus (EMC) 2A 
(both cardioviruses), had the same autonomous cleavage activity as FMDV 2A. 
Analysis of these sequences revealed a common motif of this kind of elements: a 
non-conserved N-terminus with strong α-helical propensity (which may be important 
for 2A reaction) followed by a conserved motif D(V/I)EXNPGP at the C-terminus of the 
peptide. As more virus genome sequences have become available, the number of 
2A-like peptides increased, as has the range of viruses known to have these elements 
(Reviewed in Luke et al., (2008) and Sharma et al., (2012)). Further, studies also 
revealed that some cellular genomes contain ‘2A-like’ peptide, such as the ones of 
Trypansoma brucei and Strongylocentrous purpuratus (Donnelly et al., 2001b and 
Heras et al., 2006). These peptides were tested in artificial polyprotein systems and 
confirmed in many cases to be active.  
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Beside research into requirements for and mechanism of the 2A reaction, the possibility 
of putting FMDV, and other 2A-like peptides to work as a tool had also been considered 
(de Felipe et al., 1999; de Felipe et al.2000; de Felipe et al., 2002; de Felipe et al., 2003; 
de Felipe et al., 2004; Liu et al., 2007; Szymczak et al., 2012). For example, in a study 
the 2A peptides (from FMDV and other viruses) was used to build polycistronic 
mRNAs that can be used in gene therapy delivery vectors (de Felipe et al., 1999). 
 
 
1.3.4 The mechanism of 2A reaction  
 
 
 
Although 2A peptides are increasingly used as research tools and are even being trialled 
in clinical applications (de Felipe et al., 1999; Szymczak et al., 2012) the mechanism of 
the 2A reaction is largely unclear. Current data and a model for the reaction based on 
these are outlined below.  
 
 
1.3.4.1 A ribosomal stall in the C-terminus of 2A 
 
     Similar to the stalling peptides such as that encoded by the uORF2 and the secM 
peptides, 2A and 2A-like sequences pause the ribosomes. The existence of pausing at 
2A was firstly suggested by an in vitro study in which translation of a 2A-containing 
protein was carried out in presence of low concentration of puromycin ( Donnelly et al., 
1997). Puromycin is an analogue of aminoacyl-tRNA which is randomly added to the 
C-terminus of nascent proteins during the translation elongation, independent of the 
nature of the codon present in the ribosomal A site. Inclusion of puromycin throughout 
translation should result in its incorporation throughout the synthesis of the polyprotein 
and lead the (random) puromycin-terminated truncation of translation products. But in 
the study a significant higher level of puromycin-terminated products (identified by 
immunoprecipitation with anti-puromycin antibodies) of the size of upstream products 
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of the 2A reaction was detected, which was suggested to reflect ribosomes staying at the 
C-terminus of 2A for a longer time than the other positions. 
 
Further evidence of a pause in translation was collected in a more recent study 
(Doronina et al., 2008). using the primer extension inhibition (toeprint) technique, in 
which reverse transcriptase is used to map the positions of ribosomes and other factors 
on RNA. When N. crassa translation extract (a very sensitive system for toeprint 
analysis) was programmed with mRNA encoding a 2A sequence, a toeprint signal at 
+16/17 nucleotides to the first base of glycine 18 condon of 2A was observed. Given 
that the toeprint of eukaryotic ribosomes map 15 to 17 nucleotides distal to the first base 
of the codon in the P site due to their size, this result not only supports the finding of 
existence of a pause but also indicates the position of the ribosome when the pause 
occurs - namely when the glycine 18 and proline 19 condons are in the P site and A site, 
respectively. 
 
 On the other hand, however, the same study also revealed that the strength of the 
toeprint signal at 2A is not as strong as at other nascent peptides that induce 
translational stalling, like the AAP leader peptide which was used as a control in these 
experiments. These data, combined with results from time course in vitro study of 2A 
where the downstream products appeared at the similar time as full-length products, 
suggests that this pause may not be as long as the samples of other short 
peptide-mediated translation pause where ribosome can be blocked for minutes. 
(Doronina et al., 2008b). 
 
 
 1.3.4.2 The involvement of eukaryotic release factors in 2A reaction 
 
As described in section 1.1.2, protein translation is a sequential and precise 
procedure with several translation factors involved. Therefore, the question of whether 
the 2A reaction, as a co-translational event, is mediated by the translation factors or 
affects the normal action of these factors, is important to discerne. 
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For uncovering factors that play a role in the 2A reaction (Doronina et al., 2008), 
expressed a reporter containing 2A in a range of S. cerevisae strains in each of which the 
activity of a specific translation factor is altered. It was found that over-expression of 
the 2A-containing protein in strains in which eRF1 or eRF3 factors were compromised, 
led a growth-inhibition, and this was observed neither in wild type cells nor RF 
compromised cells with no or low 2A expression. Further experiments revealed that the 
readthrough rate of a separate reporter of stop codon read-through co-expressed in the 
same cells increased with the expression of the wild 2A but not inactive 2A mutant. This 
suggests that availability of RF or its activity is reduced by 2A expression. These results 
suggest that ribosomes at 2A may recruit RF while the ribosome pause at 2A and leave 
insufficient RF for normal translation. However, the fact that the 2A induced 
translational pause is comparatively short weakens this argument (Doronina et al., 
2008). 
 
 The effects of compromised RF on the 2A reaction were also investigated in the 
same study. The results gained in in vitro and in vivo experiments revealed that, while 
reduced eRF1 activity led the 2A activity declining, compromised GTPase activity of 
eRF3, interestingly, increased the proportion of 2A upstream products and decreased 
both of those of full-length and downstream products. Considering the conventional role 
of eRF3 in translation, one possible explanation of this effect is that in 2A reaction, 
eRF3, a GTPase, assists eRF1 released from the ribosome and therefore compromised 
eRF3 may induce a longer time during eRF1 combining with ribosome and yielding 
more upstream products (Doronina et al., 2008).        
 
 1.3.4.3 The outline of the model of 2A reaction 
     
Summarizing the data obtained so far, a model of the 2A reaction, comprising 3 steps 
can be proposed (Figure 1.5).  
 
The first step is the translation of upstream product and the 2A peptide up to and 
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including the penultimate amino acid, glycine. The ribosome then pauses, presumably 
(like other peptides arrested ribosome) due to the interactions between the ribosome exit 
tunnel and the 2A peptide, leaving the penultimate glycine and final proline codon in the 
P and A site of the ribosome respectively. Due to some as yet undefined reason, (perhaps 
the specific spatial conformation of the peptide and tRNAs), the peptide bond between 
glycine and proline is not formed.  
 
The second step is the hydrolytic release of upstream product from tRNA. As 
mentioned above, there is clear evidence (Doronina et al., 2008) that release factors are 
involved in this process, but how 2A recruits these factors and their specific role in the 
reaction is still not entirely defined. 
 
The third step of 2A reaction is restart of translation from C-end proline of 2As, this 
territory still remains uncharted, and no factors have been identified that influence this 
step in the reaction.     
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Figure 1.5 Outline model of 2A reaction. See text for details.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34 
 
1.4  Aims of present study 
 
The general aim of the study presented in this thesis was to extend the knowledge of the 
mechanism of 2A reaction. This was realized by two aspects of research: 
 
1) A site-specific mutagenesis study on the 2A sequence: the aim of the site-specific 
mutagenesis was to analysis the functional element of 2A sequence. In the studies 
before my project, a random mutagenesis study was employed to analyze the 2A 
sequence, here my aim is to bring a more systematic mutation screen for 2A peptides  
 
2) The analysis of the P19X/G18X-induced ribosome stall: Examining the striking 
finding of a previous study not only offers insight of the event at the 
peptidyl-transferase centre, but also give a perspective to the further structural studies 
on the 2A peptides.   
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Chapter 2:  Materials and Methods 
 
 
2.1 materials 
 
In present study, reagents and chemicals, except otherwise claimed, were purchased 
from Sigma-Aldrich Chemical Co., BDH Chemicals, Fisher, or New England Biolabs. 
The common reagents, included regularly used buffers, are listed as followed: 
 
50X TAE buffer (1 litre) 242 g Tris Base, 100ml 0.5M EDTA pH 8.0, 57.2ml Glacial 
acetic acid, water to 1 L;  
 
TE buffer (10X): 10 mM Tris-HCL, 1 mM EDTA, pH 8.0; 
TEG buffer: 100 mM Tris-HCL pH8; 2 mM EDTA; 20% glucose; 
SDS/NaOH: 0.2 M NaOH, 1% (v/v) SDS; 
TBS buffer (10X): 500 mM Tris.HCl, pH 7.4 and 1500 mM NaCl; 
TBE buffer (10X): Tris Base,890 mM, Boric Acid,890 mM, EDTA (pH 8.0),20 Mm; 
Protein loading dye: 4% w/v SDS, 20% v/v glycerol, 0.125 mM Tris.HCl pH 6.8, 
0.004% w/v bromophenol blue and 100 mM DTT (added just before using); 
 
 
 
2.2 Strains and nucleotides 
 
2.2.1 Bacterial strains 
In present study, bacterial strains were mainly used as tools to produce plasmids. 
The Table 1.1 details the E. coli strains used during this project. 
 
2.2.2 Yeast strains 
In this project, yeast strains were exploited to test the separation activity of 2A and 2A 
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mutant peptides, in vitro and in vivo.  
Table 2.1 includes all yeast strains involved in present project. 
、 
Table 2.1 STRAINS 
Strains  Genotype Source 
E. coli 
DH10B F- endA1 recA1 galE15 galK6 nupG rpsL  ΔlacX74 
Φ80lacZΔM15 araD139 Δ(ara,leu)7697 mcrA 
Δ(mrr-hsdRMS-mcrBC)λ-  
J D Brown 
S. cerevisiae 
JDY4 a his3-Δ200, trp-Δ99, leu2, ade2-101, ura3-Δ99, cir
o 
J D Brown 
JDY5 α his3-Δ200, trp-Δ99, leu2, ade2-101, ura3-Δ99, ciro 
 
 
 
2.2.3 Plasmids used in this project 
The plasmids used in this project are listed in Table 2.2  
 
 
2.2.4 Oligonucleotides used during present study  
Oligonucleotides were purchased from Sigma-Aldrich Biotech, and re-suspended to 100 
pmol/µl for usage. Their sequence information are summarized in Table .2.3 
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2.3 Microbiological techniques 
 
2.3.1 Growth of the bacterial strains 
The E. coli strain was cultured at 37℃, in Luria-Bertani medium (LB, same below (1% 
w/v Tryptone; 0.5% w/v Yeast extract; 1% Sodium Chloride; Plus 2 % w/v agar for 
plate)), adding 100 µM ampicillin to select the transformants.  
 
2.3.2 Transformation of bacterial strains 
For transformation, E. coli cells were firstly prepared using CaCl2 method (section 
2.3.1.1), followed by the operation described in section 2.3.1.2. 
 
2.3.1.1 CaCl2 method for preparation of competent cells 
5 ml of LB culture of DH10-B was grown at 37℃ overnight, then diluted 200 times in 
100 ml LB. This was re-incubated until the culture reached OD600   0.4-0.5. The cells 
were incubated on ice for 10 min, then centrifuged at 5000 rpm for 5 min. The resulting 
pellets were re-suspended at cold 40 ml TfbI and incubated on ice for 5 min. The cells 
were harvested at 3000 rpm for 10 min, then re-suspended in 4 ml TfbII. These 
re-suspended cells were incubated for 15 min on ice, then pipetted into 100 or 200 µl 
aliquots and stored at -80℃. 
TfbI:  30mM KOAc, 100mM RuCl2, 10mM CaCl2, 50mM MnCl2,  15% Glycerol 
(adjusted to pH5.8 with Acetic Acid and filter sterilised).      
TfbII:  10mM MOPS, 75mM CaCl2, 10mM RuCl2 , 15% Glycerol (adjusted to pH6.5 
with KOH and filter sterilised).      
 
2.3.1.2 Transformation of competent cells 
For transforming DNA into the competent cells, cells were thawed on ice, then mixed 
with DNA (each 50 µl cells with 1 µl plasmid DNA or 5 µl of ligation mix). The 
mixture was incubated on ice for 15-30 min, heat shocked at 42℃ for 1 min and 
returned to ice for 2 min. 1 ml of LB broth was added to the mixture, then incubated at 
37℃ for 1 hour. The cells were then harvested at 2500 rpm for 2 min, the majority of 
the media was removed, cells were then re-suspended in the remaining solution and 
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spread on a LB ampicillin plate to select for the transformants.  
 
 
2.3.3 Growth of the yeast strains 
All yeast strains involved in this study were grown at 30℃, they were either propagated 
on rich YPD media (1% bacto-yeast extract, 2% peptone, 2% glucose Plus 2 % w/v agar 
for plate), or selective medium for in vivo test of the separation activity of 2A 
sequence/mutants, and selection for transformant. 
 
2.3.4 Transformation of yeast strains  
In this study, the plasmids were transformed into yeast cells using the lithium acetate 
method. For transformation, yeast cells were grown in 50 ml at 30℃ overnight and 
diluted 20 times, then re-incubated until the culture reached OD600 = 0.3-0.5. Cells were 
collected at 3000 rpm for 5 min, then re-suspended in 20 ml lithium acetate mix (0.1M 
LiOAc pH 7.3, 1XTE) and centrifuged again. The resulting pellet was re-suspended in 1 
ml same mix, then each aliquot of the re-suspended cells was mixed with 0.1-1 µg DNA, 
10 µl of 10mg/ml salmon-sperm DNA (previously heated at 100℃ for 5 min and 
returned into ice), and 700 µl of PEG mix (46%(w/v)polyethylene glycol-2000, 0.1M 
LiOAc pH7.3, 1XTE ).  The mixture was incubated at 30℃ for 1 hour then heat 
shocked at 42℃ for 15 min.  The cells were pelleted by centrifuge at 5000 rpm for 1 
min, then re-suspended in 1 ml YPD, and spread on desired selective plate for selection 
of the yeast transformants.  
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2.4 Molecular biology method  
 
2.4.1 Phenol chloroform isoamylalcohol extraction/isopropanol precipitation 
 
In present study, phenol chloroform isoamylalcohol (PCI) extraction was used to isolate 
and/or concentrate DNA and RNA from aqueous solution. The target solution was 
mixed with the equal volume of phenol chloroform isoamylalcohol (optimized pH for 
DNA: 5.5; for RNA: 4.5) thoroughly by vortex for 5 min. The mixture was centrifuged 
at 13000 rpm for 3 min, and the upper aqueous phase containing the nucleic acid was 
taken. This extraction might repeat several times, until the surface of two phases got 
clean. The resulting solution from extraction was added into equal volume of 
isopropanol and 1/10 volume of 3M KOAc (pH 5.3), centrifuged at 13000 rpm for 15 
min. The pellet was washed with 70% ethanol, then resuspended in desired volume of 
TE buffer or water.   
 
2.4.2 Plasmid preparation from E. coli 
 
2.4.2.1 Mini-prep for 5 ml of culture 
The mini-prep of plasmids was maily performed using QIAprep spin kit (Qiagen) and 
Wizard plus SV DNA purification system (Promega), as protocol provided by the 
manufacturer. Besides, small scale DNA preparations were also carried out by alkakine 
lysis method (described in section 2.4.2.2). In this case, the basic operation was same as 
large scale, with certain times scaled-down. 
 
2.4.2.2 Large scale preparation of plasmid DNA 
In large scale, plasmids were prepared using alkakine lysis method. 50-100 ml of 
overnight culture was pelleted at 3500 rpm for 15 min, the cells pellet was then 
re-suspended thoroughly in 2 ml TEG buffer, then 4 ml SDS/NaOH solution was added 
and mixed gently by inversion. 2.5M NaAOc (pH 5.2) was added then again mixed by 
inversion. The contents were centrifuged as earlier. The supernatant was taken and 
mixed with equal volume of isopropanol, then centrifuged again. The resulting pellet 
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was washed by 70% ethanol, air-dried for 10 min to remove the residual ethanol. The 
washed pellets was re-suspended in 0.5 ml of TE buffer, incubated with 5 µl of 10 mg 
/ml RNase A at 37℃ for 30 min. The resulting solution was extracted with PCI 3 times 
and the aqueous phase was precipitated by adding 1/10 volume of 3M NaAOc and equal 
volum of cold isopropanol. This mixture was centrifuged at 13000 rpm, then the DNA 
pellet, after washed by 70% ethanol, was resuspended in 100µl of TE or water.       
 
2.4.3 Polymerase chain reaction(PCR) 
The polymerase chain reactions (PCR) were used in this study not only for 
amplification specific regions of DNA, but also as a tool to introduce the mutations into 
DNA sequence. 
 
2.4.3.1 Reaction mixture 
Standard PCR reaction were performed as follows: 
Mixture (100µl total volume): 
1 µl    DNA template 
1 µl    oligonucleotide primer 1 (100 µM) 
1 µl    oligonucleotide primer 2 (100 µM)  
10µl 10x PCR buffer (100mM Tris pH8.3, 500mM KCL, 20mM MgCl2, 0.1% w/v 
gelatin) 
10 µl  10x PCR dNTPs (2 mM each) 
1 µl    taq DNA polymerase 
76 µl  ddH2O   
 
2.4.3.2 Programme 
 
The Standard Programme as follow: 
60 sec  at 95℃ (initial denaturing step) 
20 sec  at 95℃ (cyclic denaturing step) 
30 sec  at 53℃ (cyclic annealing step) 
120 sec  at 72℃ (initial extension step) 
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300 sec  at 72℃ (final polishing step) 
 
In practice, in term of generation of mutants, a touchdown programme (annealing 
temperature ranged from 65℃ to 50℃) was applied. During present study, all PCR reaction 
were performed in a Takara PCR Thermal Cycler.  
 
2.4.3.3 PCR products purification 
For isolation of amplified DNA from reaction mixture, purification was performed 
using Qiagen gel purification kit, as manufacturer’s instruction, or with PCI 
extraction/isopropanol precipitation. 
 
2.4.4 DNA digestion 
 
A standard DNA digestion in present study was performed as follow: 
 
2 µl  DNA (0.1-2µg) 
1 µl  desired restriction enzyme(s) 
2 µl  digestion buffer (depends the enzyme(s) used) 
 
ddH2O  to 20 µl 
 
The mixture was incubated at 37℃ (or appropriate temperature depends of enzyme 
used) for 1 hour then run on 1-2% agarose gel containing 0.005% ethidium bromide in 
1x TA buffer, to check the result.  
 
2.4.5 Oligoes annealing protocol 
Two complementary oligo were re-suspended in the annealing buffer, into 100 pmol. 
The mixture of oligos was then put into PCR tubes. The tubes were incubated on a 
thermal cycler and using the following program: 1) 95℃ for 2 minutes, 2) 25℃ for 30 
minutes. The resulting annealing product was used in DNA ligations at 4℃. 
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The annealing buffer was: 100 mM Potassium Acetate, 30mM HEPES (pH 7.5). 
 
2.4.6 DNA ligation 
 
For ligation reactions, the digested vector and DNA fragment were isolated by using 
PCI extraction/ isopropanol precipitation, and follow mixture was assembled: 
 
1 µl  Vector  (50-200ng)                  
2 µl  DNA fragment (molar ratio to the vector was 5:1) 
2 µl  10x T4 DNA ligase buffer  
1 µl   DNA ligase 
 
ddH2O  to 20 µl 
 
The mixture was incubated at 25℃ for 1 hour or 4℃ overnight, then taken 10µl for 
E.coli transformation. 
 
 
 
2.5 Western blot techniques 
 
The western blot was used in this study for the verification of the extra protein binds 
appeared in in vitro translation experiment. Therefore, samples were protein mixture 
generated by in vitro translation system, rather than extracted from cells.  
 
2.5.1 SDS-polyacrylamide gel electrophoresis 
 
Due to the small size of target protein, samples were separated using a 10% 
SDS-polyacrylamide Tris-Glycine gel. After 2 hours running at 120V, the gel was either 
stained and fixed with Coomassie blue for 2A activity assay, or used for transfer to 
electro-transmembrane for western bloting. 
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The composition of 10% SDS-polyacrylamide Tris-Glycine gel: 
 
1) Resolving gel (10 ml) 
2.5 ml resolving gel buffer (1.5M Tris.HCl pH 8.8) 
2.5 ml 40% w/v acrylamide 
1.5 ml 2% w/v bis-acrylamide 
0.1 ml 10% w/v SDS 
3.25 ml H2O 
4 µl TEMED 
167 µl 10% w/v ammonium persulphate 
 
2) Stacking gel (10 ml): 
1.25 ml stacking gel buffer (1M Tris.HCl pH 6.8) 
1.25 ml 40% w.v. acrylamide 
0.66 ml 2% w/v bis-acrylamide 
0.1 ml 10% w/v SDS 
6.4 ml H2O 
5 µl TEMED 
120 µl 10% w/v ammonium persulphate 
 
 
2.5.2 Transmembrane and blot 
 
For western bloting, the protein separated by electrophoresis was transferred onto 
Protran nitrocellulose membrane (Schleicher and Schuell) using Biorad blotting 
apparatus at 20V for 1 hour. The membrane was stained by Ponceau for 3-4 min for 
visualization of transferred protein, then blocked by incubating in blotto (5% (w/v) 
non-fat milk, 0.5% (w/v) Tween 20, 1x TBS buffer), for 30 min. The membrane was 
then incubated with primary antibody (diluted 1000 times in blotto) at 4℃ overnight or 
room temperature for 2 hours. The blocked membrane was washed with blotto for 5 min 
three times, then incubating with secondary antibody (diluted 2000 times in blotto) for 1 
hour. The membrane was washed 3 times in blotto (5 min each) followed by three times 
with TBS. The membrane was then incubated with ECL solution (12.5 mM luminol in 
DMSO, 0.2 mM p-coumaric acid, and 18% (w/v) H2O2 added before use), for 30 
seconds to 2 min. X-ray film was used to detect the light emitted. 
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2.6 in vitro transcription/translation 
 
In the present study, in vitro translations were used to test the separation activity of 
various 2A and 2A mutant sequences and generate the ribosome-peptide complex.   
 
2.6.1 in vitro translation with coupled reticulocyte lysate 
 
Coupled in vitro translation generated proteins from DNA substrate. In the project 
described in this thesis, coupled in vitro translation was performed with TNT T7 
Coupled Reticulocyte Lysate System (promega). The operation was applied as 
manufacturer’s recommended with several modifications as follows: 
 
The follow reaction mix was assembled: (for 5µl reaction) 
 
2.5µl    Rabbit reticulocyte lysate (hand-warmed from -80℃) 
0.2µl    Reaction buffer  
0.1µl    T7 RNA polymerase 
0.1µl    Amino acid mixture, minus Methionine, 1mM  
0.2µl    [S
35
]methionine, 1000Ci/mmol at 10 mCi/ml) 
0.1µl    RNasin Ribonuclease inhibitor, 40u/µl (not for generating the 
ribosome-peptide complex) 
100 ng   DNA template 
 
Nuclease-free water to final volume of 5µl. 
 
The mixture was then incubated at 30℃ for 1 hour (for activity assay) or 20 min (for 
production of ribosome-19X complex), then loaded onto a SDS-polyacrylamide gel or 
Nu-PAGE gel. 
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2.6.2 in vitro transcription 
 
For generating mRNA from DNA substrate, in vitro transcription was applied with 
RiboMAX™ Large Scale RNAProduction System SP6 (promega). The follow reaction 
was assembled as protocol: 
 
4 µl       SP6 transcription 5X buffer 
4 µl       rNTPs (25 mM ATP, CTP, UTP and 3 mM GTP) 
1-2 µg    DNA template (linearized by restriction enzyme and treated with PCI 
extraction/ isopropanol precipitation) 
1.5 µl     Ribo m
7
G cap analog, 40 mM  (purchased from promega) 
2 µl       Enzyme mix (SP6) 
 
Nuclease-free water to final volume of 20 µl. 
  
(The cap-analog here was for generated the 5’-end capped mRNA that was competent 
for in vitro translation.)    
 
The mixture was incubated at 37 ℃  for 5 hours, then treated with PIC 
extraction/isopropanol precipitation. The production of mRNA could be used directly 
for in vitro translation or stored at -80℃. 
 
2.6.3 in vitro translation with reticulocyte lysate 
 
Uncoupled in vitro translation was to produce generate protein from mRNA substrate. In 
this study, 3 kinds of different system were used for different aims. 
 
The reticulocyte lysate used was Flexi® Rabbit Reticulocyte Lysate System (promega). 
The follow mixture was assembled according the protocol: 
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3.3µl       Flexi Rabbit reticulocyte lysate 
0.1µl       Amino acid mixture, minus Methionine, 1mM 
0.2µl      [S
35
]methionine, 1000Ci/mmol at 10 mCi/ml) 
0.14µl     KCl, 2.5M  
500 ng      RNA substrate (generated from 2.6.2) 
 
Nuclease-free water to final volume of 5µl. 
 
The mixture was incubated at 30℃ for 15-20 min, then ran on the Nu-PAGE gel 
immediately as described in section 2.6.6   
 
 
2.6.4 in vitro translation with wheat germ lysate 
 
The wheat germ lysate used in this study was Flexi® Rabbit Reticulocyte Lysate 
System (promega). The follow mixture was assembled according the protocol: 
 
2.5µl         Wheat germ extract 
0.4µl         Amino acid mixture, minus Methionine, 1mM 
0.1µl         [S
35
]methionine, 1000Ci/mmol at 10 mCi/ml) 
500 ng        RNA substrate (generated from 2.6.2) 
 
Nuclease-free water to final volume of 5µl. 
 
The mixture was incubated at 30℃ for 15-20 min, then run on the Nu-PAGE gel 
immediately as described in section 2.6.6   
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2.6.5 in vitro translation with yeast extract 
 
The yeast lysate used here was laboratory-made from strain JDY5. For in vitro 
translation, the mixture was assembled as follow: 
 
1.2µl      KOAc, 1M 
2.3µl      Reaction buffer (25 ml ‘6X buffer’ plus 3µl creatine phosphokinase, and 
7µl [S
35
]methionine) 
3.3µl      Yeast lysate  
500 ng     RNA substrate (generated from 2.6.2) 
 
Nuclease-free water to final volume of 10µl. 
The mixture was incubated at 22℃ for 15-20 min, then ran on the Nu-PAGE gel 
immediately as described in section 2.6.6   
 
‘6X buffer’:  
66µl       1M HEPES-KOH pH 7.4,  
6µl        1M Mg(oAc)2 ,  
93.8µl      800 mM creatine phosphate,  
22.5µl      100 mM ATP,  
3µl         100 mM GTP, 
120µl       Amino acid mixture, minus Methionine, 1mM 
5.1µl       1M  DDT, 
183.6µl   nuclease-free water    
 
 
2.6.6 Nu-PAGE gel 
 
For detection of ribosome-peptide complex, the Nu-PAGE gel (Invitrogen) was used to 
separate the samples synthesized by in vitro translation. 
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In this project, the samples were mixed with protein loading dye as described in 2.1, 
with adjustment of pH to 8.5 using NaOH. The samples were then run on the gel at 195 
V for 30-40 min in 1X MES SDS running buffer. The gel was fixed in the fixing 
solution for at least 1 hour. The radioactivity signal of protein containing 
[S
35
]methionine were detected by follow protocol described in section 2.6.7.  
 
20 X MES SDS Running Buffer: (for 40 ml) 
 
9.76 g      MES                                                    
6.06 g      Tris Base                                            
1 g         SDS                                                     
0.3 g        EDTA     
40 ml      nuclease-free water. 
 
 
Fixing solution: (for 550 ml) 
 
180 ml  ethanol 
100 ml formaldehyde 
10-20 ml of glycerol (otherwise gel cracks during drying) 
240 ml deionised water 
                                                   
 
2.6.7 Exposure to phosphor screen and analysis 
 
In the study described in this thesis, the purse of radioactively labeled protein was 
detected by phosphor screen. 
 
After running, the SDS-polyacrylamide gels were fixed with coomassie blue for 2 hours, 
then treated with DESTIN solution for 30 min; for Nu-PAGE gel, the gel was fixed with 
fixing solution for 1 hour. 
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The fixed gel was then dried with gel drier (Labconco) at 80℃ for 2 hours, and blocked 
with a phosphor image a phosphor image (BAS-MP 2040S) in a cassette, exposure for 2 
hours to 2 days. The image was screen on the Typhoon Tiro scanner to detect the signal.      
 
 
 
 
2.6.8 Inhibition of protease  
 
For inhibition of the potential protein degradation during the in vitro translation, two 
protease inhibitors were tested in this study: 
 
1) phenylmethylsulfonyl fluoride (PMSF): was made up to 100 mM in isopropanol and 
then added into the reaction mixture with a final concentration of 0.5 or 1 mM; 
2) complete EDTA-free (Roche) mini protease inhibitor tablets (CMEF) : was added 
into reaction with a proportion of 1 tablets to 50 ml reaction mixture. 
 
 
 
 
2.7 Purification of ribosome-peptide complex (RNC) 
 
In this project, the method of RNC (with a polyhis-tag) purification from in vitro 
translation mixture was based with the one described in (Halic et al., 2004) with several 
modifications. 
 
After in vitro translation described in 2.6, 40µl fresh samples (8X scale up as described 
in 2.6) was terminated with 2µl of 2 mg/ml cycloheximide, then carefully layered on a 
600µl high-salt sucrose cushion in a centrifuge tube (Beckman Polycarbonate 11x34 
mm). The tube was gently placed into an Optima TLX Ultracentrifuge (Beckman), spun 
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at 100000 rpm for 2 hours. The resulting pellet was resuspended in 40µl 250 buffer, 
(this step need 4 hours to overnight) then mixed with magnetic beads from 100µl rinse. 
The resulting mixture was incubated on a rotary sharker for 1 hour at 4℃, then the 
beads were collected and the supernatant was removed. The beads were washed with 
0.5 ml 250 buffer and then 0.2 ml 500 buffer. The beads were then washed with 10 mM 
imidazole solution. The RNC was eluted by washing with 100 mM imidazole solution 2 
times. The elutions containing RNC were collected, and analyzed on a Nu-PAGE gel as 
described in 2.6.6. 
 
High-salt sucrose cushion: 50mM Tris-HCl (pH 7.0), 500mM potassium acetate, 25mM 
magnesium acetate, 2mM dithiothreitol (DTT), 1M sucrose and 10µg/ml cycloheximide 
added immediately before use  
250 buffer: 50mM Tris-HCl (pH 7.0), 250mM potassium acetate, 25mM magnesium 
acetate, 0.1% (w/v) Nikkol, 5mM β-mercaptoethanol, 250mM sucrose, and 10µg/ml 
cycloheximide added immediately before use 
500 buffer: 250 buffer containing 500mM potassium acetate 
10 mM imidazole solution:    250 buffer containing 10 mM imidazole 
100 mM imidazole solution:  250 buffer containing 100 mM imidazole 
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Table 2.2 PLASMIDS 
 
Plasmid Insert Vector Source 
pJNY58 Ub-R-2A-ADE2 pRS314 
TRP1, CEN6, ARS4 
J D Brown 
(lab) pJNY57 Ub-R-2A
P17A
-ADE2
 
pPS30   Ub-R-2A
E14Q
-ADE2 
pJNY58 
TRP1, CEN6, ARS4 
P Sharma 
pPS31   Ub-R-2A
S15I
-ADE2 
pPS33   Ub-R-2A
N16H
-ADE2 
pPS34   Ub-R-2A
N16E
-ADE2 
pPS35   Ub-R-2A
N16Q
-ADE2 
pFYY1 Ub-R-2A
P19A
-ADE2 
This study 
pFYY2 Ub-R-2A
P19E
-ADE2 
pFYY3 Ub-R-2A
P19G
-ADE2 
pFYY4 Ub-R-2A
P19K
-ADE2 
pFYY5 Ub-R-2A
P19R
-ADE2 
pFYY6 Ub-R-2A
S15A
-ADE2 
pFYY7 Ub-R-2A
S15E
-ADE2 
pFYY8 Ub-R-2A
S15F
-ADE2 
pFYY9 Ub-R-2A
S15G
-ADE2 
pFYY10 Ub-R-2A
S15T
-ADE2 
pFYY11 Ub-R-2A
S15P
-ADE2 
pFYY12 Ub-R-2A
V13A
-ADE2 
pFYY13 Ub-R-2A
V13E
-ADE2 
pFYY14 Ub-R-2A
V13F
-ADE2 
pFYY15 Ub-R-2A
V13G
-ADE2 
pFYY16 Ub-R-2A
V13K
-ADE2 
pFYY17 Ub-R-2A
V13L
-ADE2 
pFYY18 Ub-R-2A
V13P
-ADE2 
pFYY19 Ub-R-2A
G11A
-ADE2 
pFYY20 Ub-R-2A
G11H
-ADE2 
pFYY21 Ub-R-2A
G11K
-ADE2 
pFYY22 Ub-R-2A
G11P
-ADE2 
pFYY23 Ub-R-2A
L1V
-ADE2 
pFYY24 Ub-R-2A
L6F
-ADE2 
pFYY25 Ub-R-2A
L2W
-ADE2 
pFYY26 Ub-R-2A
F4L
-ADE2 
pFYY27 Ub-R-2A
L1G
-ADE2 
pFYY28 Ub-R-2A
L2G
-ADE2 
pFYY29 Ub-R-2A
N3G
-ADE2 
pFYY30 Ub-R-2A
F4G
-ADE2 
pFYY31 Ub-R-2A
D5G
-ADE2 
pFYY32 Ub-R-2A
L6G
-ADE2 
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pFYY33 Ub-R-2A
L7G
-ADE2 
pJNY58 
TRP1, CEN6, ARS4 
This study 
pFYY34 Ub-R-2A
K8G
-ADE2 
pFYY35 Ub-R-2A
L9G
-ADE2 
pFYY36 Ub-R-2A
A10G
-ADE2 
pFYY37 Ub-R-2A
D12G
-ADE2 
pFYY38 Ub-R-2A
E14G
-ADE2 
pFYY39 Ub-R-2A
N16G
-ADE2 
pFYY40 Ub-R-2A
P17G
-ADE2 
pFYY41 Ub-R-2A
L1P
-ADE2 
pFYY42 Ub-R-2A
L2P
-ADE2 
pFYY43 Ub-R-2A
F4P
-ADE2 
pFYY44 Ub-R-2A
L7P
-ADE2 
pFYY45 Ub-R-2A
A10P
-ADE2 
pFYY46 Ub-R-2A
G19P
-ADE2 
pFYY47 Ub-R-2A
L2W+F4L
-ADE2 
pFYY48 Ub-R-2A
L1V+L6F
-ADE2 
pLH135 GFP-2A-PAC 
In vitro translation 
Using T7 promotor 
R Martin 
(lab) pLH136 GFP-2A
P17A
-PAC 
pFY1 GFP-2A
P17A
-PAC 
This study 
pFY2 GFP-2A
E14Q
-PAC 
pFY3 GFP-2A
S15I
-PAC 
pFY4 GFP-2A
N16H
-PAC 
pFY5 GFP-2A
N16E
-PAC 
pFY6 GFP-2A
N16Q
-PAC 
pFY7 GFP-2A
P19A
-PAC 
pFY8 GFP-2A
P19K
-PAC 
pFY9 GFP-2A
L1V
-PAC 
pFY10 GFP-2A
L6F
-PAC 
pFY11 GFP-2A
L2W
-PAC 
pFY12 GFP-2A
F4L
-PAC 
pFY13 GFP-2A
L2W+F4L
-PAC 
pFY14 GFP-2A
L1V+L6F
-PAC 
pFY15 GFP-2A
L1G
-PAC 
pFY16 GFP-2A
L2G
-PAC 
pFY17 GFP-2A
N3G
-PAC 
pFY18 GFP-2A
F4G
-PAC 
pFY19 GFP-2A
D5G
-PAC 
pFY20 GFP-2A
L6G
-PAC 
pFY21 GFP-2A
L7G
-PAC 
pFY22 GFP-2A
K8G
-PAC 
pFY23 GFP-2A
L9G
-PAC 
pFY24 GFP-2A
A10G
-PAC 
pFY25 GFP-2A
D12G
-PAC 
pFY26 GFP-2A
V13G
-PAC 
pFY27 GFP-2A
E14G
-PAC 
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pFY28 GFP-2A
S15G
-PAC 
In vitro translation 
Using T7 promotor 
This study 
pFY29 GFP-2A
N16G
-PAC 
pFY30 GFP-2A
P17G
-PAC 
pFY31 GFP-2A
P19G
-PAC 
pFY32 GFP-2A
L1A
-PAC 
pFY33 GFP-2A
L2A
-PAC 
pFY34 GFP-2A
N3A
-PAC 
pFY35 GFP-2A
F4A
-PAC 
pFY36 GFP-2A
D5A
-PAC 
pFY37 GFP-2A
L6A
-PAC 
pFY38 GFP-2A
L7A
-PAC 
pFY39 GFP-2A
K8A
-PAC 
pFY40 GFP-2A
L9A
-PAC 
pFY41 GFP-2A
G11A
-PAC 
pFY42 GFP-2A
D12A
-PAC 
pFY43 GFP-2A
V13A
-PAC 
pFY44 GFP-2A
E14A
-PAC 
pFY45 GFP-2A
S15A
-PAC 
pFY46 GFP-2A
N16A
-PAC 
pFY47 GFP-2A
P17A
-PAC 
pFY48 GFP-2A
G18A
-PAC 
pFY49 GFP-2A
P19A
-PAC 
pFY50 GFP-2A
L1P
-PAC 
pFY51 GFP-2A
L2P
-PAC 
pFY52 GFP-2A
N3P
-PAC 
pFY53 GFP-2A
F4P
-PAC 
pFY54 GFP-2A
D5P
-PAC 
pFY55 GFP-2A
L6P
-PAC 
pFY56 GFP-2A
L7P
-PAC 
pFY57 GFP-2A
K8P
-PAC 
pFY58 GFP-2A
L9P
-PAC 
pFY59 GFP-2A
A10P
-PAC 
pFY60 GFP-2A
G11P
-PAC 
pFY61 GFP-2A
D12P
-PAC 
pFY62 GFP-2A
V13P
-PAC 
pFY63 GFP-2A
E14P
-PAC 
pFY64 GFP-2A
S15P
-PAC 
pFY65 GFP-2A
N16P
-PAC 
pFY66 GFP-2A
G18P
-PAC 
pFY67 GFP-2A
TMEV
-PAC 
pFY68 GFP-2A
EMCV
-PAC 
pFY69 GFP-2A
10T+9F
-PAC 
pFY70 GFP-2A
9T+10F
-PAC 
pFY71 GFP-2A
9F+10T
-PAC 
pFY72 GFP-2A
9F+10E
-PAC 
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pFY73 GFP-2A
9E+10F
-PAC 
In vitro translation 
Using T7 promotor 
This study 
pFY74 GFP-2A
A10I
-PAC 
pFY75 GFP-2A
L9K
-PAC 
pFY76 GFP-2A
L7Q
-PAC 
pFY77 GFP-2A
L7D
-PAC 
pFY78 GFP-2A
A10I+G11H
-PAC 
pFY79 GFP-2A
L9K+G11H
-PAC 
pFY80 GFP-2A
L7Q+G11H
-PAC 
pFY81 GFP-2A
L7D+G11H
-PAC 
pFY83 GFP-2A
KQ
-PAC
1
 
pFY84 GFP-2A
YYKQ
-PAC
2
 
pFY85 GFP-2A
P19X
-PAC 
pFY86 GFP-2A
G18X
-PAC 
pFY87 GFP-2A
P17X
-PAC 
pFY88 GFP-2A
K8X
-PAC 
pFY89 GFP-2A
P17A+P19X
-PAC 
pJN141 pro-α-factor-2A-prolactin 
In vitro translation 
Using SP6 promotor 
V Doronina 
pJN275 Histag-pro-α-factor-2A-PLL 
pJN275M4 Histag-pro-α-factor-2A-PLL
3
 
This study 
pFY90 Histag-pro-α-factor- 
2A
 TMEV(T15S)
-PLL 
pFY91 Histag-pro-α-factor- 
2A
IMNV
-PLL 
pFY92 Histag-pro-α-factor- 
2A
 Prv-1
-PLL 
 
 
 
 
1. ‘KQ’ refers to the FMDV 2A mutant L6K+L7Q+G11H 
2. ‘YYKQ’ refers to the FMDV 2A mutant F4Y+D5Y+L6K+L7Q+G11H 
3. See section 6.2.1 for detail 
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Table 2.3 OLIGOS 
 
Oligo Name Sequence (5’-3’) Refer to 
Section 
Ubi5  CCAGGAATCCATGCAGATTTTCGTC 
Section 3.1 
AD3 GTGTAGGAACATCAACATGCTC 
135SEQ CGGATCGACGGTGTGG 
135SEQ long TGCCGATGTCGAGCC 
EMCVfor CTAGAGGAGCATGCCACTACGCTGGTTACTTTGC
GGACCTACTGATTCATGACATTGAGACAAATCCC
GGGCC 
Section 
5.2.1 
EMCVrev CGGGATTTGTCTCAATGTCATGAATCAGTAGGTC
CGCAAAGTAACCAGCGTAGTGGCATGCTCCT 
TMEVfor CTAGAGGAGCATGCTACCATGCTGACTACTACAA
ACAGAGACTCATACATGATGTAGAAATGAACCCC
GGGCC 
TMEVrev CGGGGTTCATTTCTACATCATGTATGAGTCTCTGT
TTGTAGTAGTCAGCATGGTAGCATGCTCCT 
F+Efor CTAGAGGAGCATGCCAGCTGTTGAATTTTGACCT
TCTTAAGCTTATTCATGACATTGAGACAAATCCCG
GGCC 
Section 
5.2.2 
F+Erev CGGGATTTGTCTCAATGTCATGAATAAGCTTAAG
AAGGTCAAAATTCAACAGCTGGCATGCTCCT 
F+Tfor CTAGAGGAGCATGCCAGCTGTTGAATTTTGACCT
TCTTAAGCTTGCGCATGATGTTGAAATGAATCCTG
GGCC 
F+Trev CAGGATTCATTTCAACATCATGCGCAAGCTTAAG
AAGGTCAAAATTCAACAGCTGGCATGCTCCT 
T+Ffor CTAGAGGAGCATGCTACCATGCTGACTACTACAA
ACAGAGACTCGCGGGAGACGTCGAGTCCAACCC
TGGG-CC 
T+Frev CAGGGTTGGACTCGACGTCTCCCGCGAGTCTCTG
TTTGTAGTAGTCAGCATGGTAGCATGCTCCT 
E+Ffor CTAGAGGAGCATGCCACTACGCTGGTTACTTTGC
GGACCTACTGGCGGGAGACGTCGAGTCCAACCC
TGGGCC 
E+Frev CAGGGTTGGACTCGACGTCTCCCGCCAGTAGGTC
CGCAAAGTAACCAGCGTAGTGGCATGCTCCT 
T+F2for CTAGAGGAGCATGCTACCATGCTGACTACTACAA
ACAGAGACTCATAGGAGACGTCGAGTCCAACCC
TGGGCC 
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T+F2rev CAGGGTTGGACTCGACGTCTCCTATGAGTCTCTG
TTTGTAGTAGTCAGCATGGTAGCATGCTCCT 
Section 
5.2.2 
YYKQfor CTAGAGGAGCATGCCAGCTGTTGAATTATTATAA
ACAAAAGCTTGCGCACGACGTCGAGTCCAACCC
TGGGCC 
Section 
5.2.3 
YYKQrev CAGGGTTGGACTCGACGTCGTGCGCAAGCTTTT
GTTTATAATAATTCAACAGCTGGCATGCTCCT 
KQ-for CTAGAGGAGCATGCCAGCTGTTGAATTTTGACAA
ACAAAAGCTTGCGCACGACGTCGAGTCCAACCC
TGGGCC 
KQ-rev CAGGGTTGGACTCGACGTCGTGCGCAAGCTTTT
GTTGTCAAAATTCAACAGCTGGCATGCTCCT 
T3 AATTAACCCTCACTAAAGGG 
Section 
6.1.1 
T7 AATACGACTCACTATAGG 
SP6 CATTTAGGTGACACTATAG 
275for AATTCAGATATCCATAGTTCAAACAAGAAGATT
ACAAACTATCAATTTCATACACAATATAAACGG
CCGCCACCATGGTA 
Section 
6.2.1 
275rev AATTTACCATGGTGGCGGCCGTTTATATTGTGTA
TGAAATTGATAGTTTGTAATCTTCTTGTTTGAAC
TATGGATATCTG 
SEQ141 AATGAACCCTTTGCC 
M4forTMEV  CTAGGGCATGCGCAGTACGAGGATACCACGCAG
ACTACTACAAACAACGACTAATACACGACGTCGA
GTCCAACCCTGGGCC 
Section 
6.1.2 
M4revTMEV CAGGGTTGGACTCGACGTCGTGTATTAGTCGTTG
TTTGTAGTAGTCTGCGTGGTATCCTCGTACTGCGC
ATGCC 
 
M4forPrv-1 CTAGGGCATGCAACTCAGGATACGTAGTAGGAGG
ACGAGGATCACTACTAACATGCGGAGACGTCGA
GTCCAACCCTGGGCC 
M4revPrv-1 CAGGGTTGGACTCGACGTCTCCGCATGTTAGTAG
TGATCCTCGTCCTCCTACTACGTATCCTGAGTTGC
ATGCC 
 
M4forIMNV CTAGGGCATGCGAAATATCAGACTGCATGCTACC
ACCACCAGACCTAACATCATGCGGAGACGTCGA
GTCCAACCCTGGGCC 
M4revIMNV CAGGGTTGGACTCGACGTCTCCGCATGATGTTAG
GTCTGGTGGTGGTAGCATGCAGTCTGATATTTCG
CATGCC 
 
Pur-17A TTAGGCCCCGGGCCCGGCGTTGGACTCGACGTC
TCC 
Section 
6.2.2 
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Pur-19x TTAGGCCCCTTACCCAGGGTTGGACTCGACGTCT
CC 
Section 
6.2.2 
Pur-wt TTAGGCCCCGGGCCCAGGGTTGGACTCGACGTC
TCC 
Pur-19x17A TTAGGCCCCTTACCCGGCGTTGGACTCGACGTCT
CC 
 
 
Note: Due to the number and similarity, the oligoes used to generate FMDV 2A mutants 
from pJNY58 is not listed in table 2.3. See section 3.1 for detail. 
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Chapter 3: Site-specific mutagenesis analysis of 2A sequence  
 
 
 
 
The project described in this thesis follows on from that of a former PhD student in the 
laboratory, Dr. Pamila Sharma. During her study, Dr. Sharma carried out a random 
mutagenesis of the FMDV 2A sequence to identify the key elements within it. The first 
part of the present study was a complementary site-specific mutagenesis study, to 
extend her finding. 
 
This chapter summarizes the key findings of the previous screen, and the first part of 
present study. Before this however, an introduction is to give for the methods used for 
site-specific mutagenesis and the assays of 2A separation activity, which were the main 
strategy not only for the study described in this chapter, but also for that of chapters 4 
and 5. 
 
 
 
 
 
3.1 2A activity reporter systems 
 
The activity of various 2A sequences and 2A mutants were reported by 2 independent 
systems: an in vivo assay that exploited the varied colour (white to red) of yeast 
expressing reducing amounts of Ade2p and an in vitro translation assay. The 2A used in 
these experiments was, with the exception of some experiments reported in Chapter 5, 
from FMDV.   
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3.1.1 In vivo reporter 
 
The in vivo reporter system used in this study (Ub-R-2A/2A*-ADE2) was constructed 
by Jeremy Brown and published in (Sharma et al., 2012). This reporter comprises a 
fusion of sequences encoding ubiquitin, a single arginine, 2A or 2A mutants and Ade2p 
into a single open reading frame (UBI-R2A-ADE2). The vector that hosts this open 
reading frame is pRS314, a low copy (CEN) S. cerevisiae-E.coli shuttle plasmid 
containing the TRP1 marker for selection in yeast (Sikorski et al., 1989). For the 
activity assay, this construct and variants of it containing different 2A mutants were 
transformed into S. cerevisiae (strain JDY4, see Table 2.1).  
 
In S. cerevisiae, Ade2p is a key enzyme in synthesis of purine nucleotides 
converting phosphoribosylaminoimidazole (AIR) into phosphoribosylaminoimidazole 
carboxylate (CAIR), which is then converted into SAICAR by Ade1p.(Figure 3.1) Both 
AIR and CAIR are toxic to the cell and are oxidised and transported to the vacuole, 
where they accumulate as red-coloured derivatives. Therefore, cells lacking functional 
Ade2p or Ade1p grow as red colonies, particularly when adenine is limited in the media 
as this results in induction of the adenine biosynthesis pathway.  
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Figure 3.1: The Adenine Metabolic Pathway. Take notice on the crucial roles of ADE1 
and ADE2 in transformation of AIR to SAICAR (Highlighted by gray rectangle). Taken 
from Rebora et al., (2001). 
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In cells transformed with the above-mentioned reporter where a mutation has been 
introduced into 2A that inactivates it, the translation product is the full length fusion of 
ubiquitin, arginine, 2A mutants and Ade2p. The N-terminal ubiquitin chain of this 
fusion polyprotien is proteolytically removed from the protein in the cytoplasm by 
ubiquitin-specific proteases and leaves arginine as a new N-terminus to the remainder of 
the protein. Proteins with an arginine at the N-terminus are very unstable and are rapidly 
degraded by the proteasome through the conserved N-end rule pathway (Varshavsky et 
al., 1997). Therefore, Ade2p is not stably expressed, and in otherwise, genomically ade2 
cells, such 2A mutant-containing reporters yield red or pink colonies on plates 
containing limiting amounts of adenine（see Figure 3.2a ‘pRS314’~‘E14Q’). 
 
On the other hand, ade2 cells transformed with a plasmid containing wild type 2A 
or a 2A mutant with full or partial activity, the 2A reaction co-translationally separates 
the upstream Ub-R-2A from the downstream Ade2p. This results in stable expression of 
Ade2p and AIR and CAIR will be converted via Ade2p and Ade1p into SAICAR. When 
grown on adenine-limiting plates, this yields colonies with colours ranging from white 
through varying shades of pink depending on the level of activity of the 2A/2A mutant 
(see Figure 3.2a ‘WT’). 
  
In conclusion, the fusion protein of ubiquitin, arginine, 2A or 2A mutants and 
ADE2p offers a reporter by which we can judge whether a 2A mutant is active. 
Moreover, the activity can be assessed by the relative colour development of colonies 
carrying different 2A/2A mutants.  
 
An example of this is shown in Figure 3.2a, in which previously characterised 2A 
mutants (in Donnelly et al., (2001)) are compared, by spotting suspensions of cells 
containing UBI-R2A-ADE2 reporters with the various mutants onto a plate containing a 
limited amount of adenine. Here, as expected, cells containing the reporter with wild 
type 2A remained white, while those with the mutants E14Q, S15I or N16H that were 
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reported to have partial activities (56%, 42% and 31% respectively) conferred a pink 
colour on the cells, though, due to unknown reason, the shade of pink was slightly 
deeper with E14Q (56%) than with S15I (42%). In contrast, three mutants assessed 
previously with low or null activities, N16E (19%), N16Q (10%), P17A(0%) conferred 
a red colour to the cells transformed with the reporters carrying them. These results 
indicated, in general, that the colour phenotype of the cells transformed with various 2A 
mutants fit with the reported activity of these mutants. This set of mutants was used as 
control in followed study. 
 
3.1.2 In vitro reporter  
 
The polyprotein reporter used for the in vitro analysis was a gift from Professor Martin 
Ryan of St Andrews University. It comprises CFP (cyan fluorescent protein), followed 
by 2A or 2A mutant and PAC (puromycin N-acetyltranferase) which, when 2A or 2A 
mutant is active, is divided into upstream (CFP-2A) and downstream products (PAC). 
Both CFP and PAC are preceeded by a single copy of the V5 epitope tag. This construct 
was assembled in pcDNA3.1 (Invitrogen) and transcription is driven from a T7 
promoter upstream of the open reading frame. 
 
For testing the activity of 2A or 2A mutants, the above-mentioned plasmid containing 
the target 2A sequence was used in coupled in vitro transcription-translation reactions in 
reticulocyte lysate with [35S] methionine. (as described in 2.6.1) Products were then 
resolved on 10% SDS-polyacrylamide Tris-Glycine gels (2.5.1), which were fixed and 
dried, and then analyzed by phosphorimaging (2.6.7). 
 
 
 
 
 
 
To quantify 2A activity, the incorporation of [35S] methionine into the translation 
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products
 
[CFP-2A-PAC] (full length form), and the upstream- and downstream-products
 
PAC and [CFP-2A] was determined by phosphorimaging. The photo-stimulated 
luminescence (PSL) of each band
 
was determined, background subtracted and then 
divided by the methionine content (CFP:10, PAC:10) of
 
the appropriate translation 
product (PSL
corr
). 2A activity
 
(%) was calculated as:
 
 
                   
[PSL
corr
 of CFP2A] /([PSL
corr
 of CFP2APAC]+[PSL
corr
 of CFP-2A]) 
 
     As the 2A reaction is co-translational, here we used the ratio of N-terminal 
product (CFP-2A) to full length plus N-terminal product to determine the 2A 
efficiencies, namely the percentage of ribosomes that released N-terminal product. It is 
notable that, the above formula is different to the one used in previous study, (Donnelly 
et al., 2001)  in which the 2A activity is determined by the ratio of the total of 
separated products (up- and down-stream) to the sum of all products (up- and 
down-stream products plus the full length protein). This formula measures the 
percentage of translation products resulted by the 2A reaction. 
 
 An example in vitro assay is shown in Figure 3.2b, with the same mutants set as 3.1.1. 
The quantified data (table 3.1) shared the comparable pattern as the results obtained 
previously, with an exception on mutants E14Q and S15I, of which in the previous 
study the former was significantly higher than the latter, (56% and 42%) but were very 
similar in present assay. The difference of exact value between present and previous 
study can be attributed mainly to the alteration of calculation equation. Indeed, when we 
quantified the present in vitro assay with the formula used in (Donnelly et al., 2001), 
more similar values were observed (Compare the columns 2 and 4 of table 3.1).  
 
The present data were also comparable with in vivo test, except the mutants E14Q and 
S15I, where the in vivo assay scored E14Q as less active than S15I, but in vitro assay 
revealed them to be similar, as Figure 3.2 and table 3.1 shown.  
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Figure 3.2   in vivo and in vitro assays of 2A activity on wild type 2A and 2A mutants 
P17A, N16Q, N16E, N16H, S15I and E14Q.   
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Table 3.1 Quantification data in the previous study (Donnelly et al., 2001) (column 2 
‘Previous reported’), the present assay (column 1 ‘Present assay’), and the present data 
analysed by formula used in (Donnelly et al., 2001) (column 3 ‘Present assay previous 
cal.’)  
 
 
 
3.1.2.1  A discussion of extra bands on the in vitro test 
 
SDS-PAGE gels of CFP-2A-PAC translation products revealed an ‘extra’ band at about 
50 kDa just below the full length translation product (indicated with *  in Figure 3.2b). 
Attempts were made to characterise this band as, if it was derived from CFP-2A-PAC 
taking it into account in calculating 2A activity may be important.  
 
The 50 kDa band was also observed in experiments performed in Prof. Ryan’s lab. 
(personal communication). Initially it was considered that it may be a degradation 
product from the full length protein. Therefore, protease inhibitors 
phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor tablets (Roche, Complete, 
Mini, EDTA-free were added into coupled transcription/translation reactions, and 
2A mutants Present assay 
Previous 
reported 
Present assay 
previous cal. 
WT 70.8 % ~90 % 81.7 % 
E14Q 18.5 % 56 % 32.2 % 
S15I 18.1 % 42 % 32.6 % 
N16H 9.9 % 31 % 16.4 % 
N16E 6.8 % 19 % 13.1 % 
N16Q 6.2 % 10 % 7.2 % 
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reaction times were reduced, in order to reduce any proteolysis (protocol see section 
2.6.8). However, as shown in Figure 3.3a, these measures did not affect the outcome. 
Thus the 50 kDa species may not be the production of degradation. 
 
To confirm whether or not the extra band was a part of construct [CFP-2A*-PAC], the 
products of coupled in vitro transcription translation were resolved on SDS-PAGE gels, 
transferred to nitrocellulose and probed with anti-V5 monoclonal antibodies as 
described in 2.5. As both CFP and PAC portions of the polyprotein contain a V5 epitops, 
the separated and full length translation product should all be detected by the antibody. 
Following Western blotting, phosphorimaging was used to detect the [35S] incorporated 
into the poteins during translation. The outcomes of western blot and phosphorimaging 
are shown in Figure 3.3b. The results of the two detection methods superimposed to 
each other: the 50 kDa band was detected in both cases, indicating that it must be a 
truncated version of the full length (i.e. unresolved) translation product. The mechanism 
through which this occurs still lacks explanation. One possibility is that during 
translation initiation, the minority of the initiation complexes ‘skip’ the first methionine 
and initiate translation at a second methionine, but no experiment was carried out to 
confirm this. However, a full length translation product generated from the second 
methionine in the protein has a predicted molecular weight of 45 kDa, which could be 
consistent with this possiility. Intriguingly, we found that the 50 kDa band only 
appeared while using the in vitro translation system based on reticulocyte lysate. When 
translation preformed with the same pLH135 construct but in wheat germ this product 
was not generated (figure 3.3c). Although the mechanism by which the 50 kDa band is 
generated remains unclear, it was decided to use reticulocyte lysate to assay the 2A 
activity in vitro, for the following reasons:  
 
1 The key goal of this study was to compare activity of different mutants, the loss of 
small amount of full length protein does not affect the relative activities of mutants. 
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2 When the efficiency of 2A peptides was compared between coupled 
transcription-translation and direct translation of RNA of wheat germ, similar values 
were obtained. 
 
3 With DNA as the template, the coupled system is significantly simpler to use and is 
more economic than generating RNA and then using it as a template for translation. 
This was particularly important given the large number of mutants involved in this study. 
The only coupled system available, however, is the reticulocyte lysate.   
 
 
 
   
 
 
Figure 3.3a in vitro translation on wild type 2A with protease inhibitors treatment. The 
PMSF (lane 1,4) or protease inhibitor tablets (CMEF)  (lane 3, 6), or water (lane 2,5) 
were added to the in vitro assay mix before the reaction, as protocol. The reactions were 
implemented for 15mins (lane 1~3) or 60mins (lane 4~6).  
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Figure 3.3b Western blot and western blot and phosphorimaging of wild type 2A and 2A 
mutant P19A (as an inactive control). See text for detail. ‘*’ marks the 50 kDa 
translation product discussed in the text and which may be caused by leaky scanning 
and initiation at the second methionine in the protein. 
 
 
Figure 3.3c in vitro translation in wheat germ, on the wild type 2A and inactive mutant 
P17A. See text for detail  
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3.1.3 Generation of 2A mutants 
 
 
To generate mutations in 2A of FMDV, PCR was used to amplify fragments containing 
the desired mutations from plasmid pJNY58, which contained the Ub-R-2A-ADE2 
reporter (the strategy is outlined in Figure 3.4).  
       
Primers were used specifying the desired changes to the 2A coding sequence. These 
primers were designed as reverse primers and with an NcoI site at their 5’-end. The 
forward primer used in the amplification is a common primer ‘Ubi5’ which contained a 
BamHI restriction site at the 5’-end. A touchdown PCR programme (annealing 
temperature set at 65 ℃, and reduced during the reaction to 50 ℃) was used to amplify 
the PCR fragments (see section 2.4.3). The resulting PCR fragments were then cloned 
into plasmids pJNY58 (for in vivo assay) and pLH135 (for in vitro study) using the 
BamHI and NcoI sites, and internal XbaI and ApaI sites respectively, replacing the wild 
type 2A coding sequence with the mutant (Figure 3.4). All plasmids were sequenced to 
confirm both the presence of the desired mutations within the 2A coding sequence, and 
that no other mutations had been introduced during PCR. 
 
The mutants with amino acids replacement in position 1~17th were generated as 
described above. However, it was noted that, the two final condons of 2A, Gly18 and 
Pro19, is corresponding to the ‘gggccc’ in the DNA sequence. This formed an ApaI site 
that was to be manipulated in following step of the construct of the in vitro reporter 
pLH135. Hence, the mutants related to these two positions were added an extra ApaI 
site 2 condons downstream to the 2A coding region, during design of the primers used 
to introduce the mutations.  
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Figure 3.4: The general cloning strategy for in vivo and in vitro studies, see text for 
details.       
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3.2 Summary of previous random screen 
 
 
A random mutagenesis had been carried out in the laboratory by Dr. Pamila Sharma 
prior to my studies. This was to generate a broad range of mutations in 2A, and added 
significantly to the mutants that had been generated by site-directed mutagenesis 
previously (Donnelly et al., 1997; Donnelly et al., 2001). In these studies, carried out in 
vitro, several important features of 2A sequence were revealed (see introduction section 
1.3.2 for details) However, the number of the mutants tested was relatively small. In 
addition, these mutations were largely within the C-terminal conserved motif of 2A, and 
the role of N-terminal section of the peptide was not explored. To overcome these 
limitations and provide a more complete picture of the effects of mutation of sequence 
on the function of the 2A peptide, Dr Pamila Sharma carried out a large scale random 
screen on 2A from FMDV. In that study, random mutations were introduced into the 
C-terminal portion (Asp14 to Pro19) of 2A by 2-step PCR with a primer containing 2% 
non-template nucleotide in the region corresponding to Asp14 to Pro19. In vivo gap 
repair (Muhlrad et al., 1992) incorporated the mutated sequences into Ub-R-2A-ADE2, 
and growth on plates containing limited amounts of adenine allowed identification of 
the relative activity of the mutants. A similar strategy was also applied to N-terminal 
section of 2A (Leu1-Gly11). The activity of these mutant 2A was analysed using the in 
vivo reporter system (as described in section 3.1). 400 yeast colonies containing 2A 
mutants, with different colour (white-2A not affected by mutation or Pink-2A affected 
by mutation) were selected from initial plates and the 2A coding region of the plasmids 
they contained was amplified and sequenced to identify mutations within it.   
 
From 400 colonies, 354 2A sequences were clearly identified. Excluding the ones 
without mutation or with the same mutations, 56 independent single mutants and 29 
double mutants were identified. These mutants and their 2A activity (reported by the 
colour of their host colonies) are summarize in table 3.2 
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Table 3.2 Summary of single mutants identified in previous random screen. Data are 
summarised from Dr Sharma’s previous in vivo experiments. The 2A activity was 
roughly estimated by comparison with several control mutants (E14Q, S15I, N16H, 
N16E, and N16Q)  The letters in the form represent mutation i.e. the corresponding 
amino acid replacement in the position; the colour of the letter represent the 2A activity 
of the mutation estimated by comparison to the control:  
Red refers the mutant is inactive; and the JDY4 colony give red colour; Purple refers the 
mutant having weak activity; and the JDY4 colony give deep pink colour; 
Yellow refers the mutant having significant activity; and the JDY4 colony gives light 
pink colour;green refers the mutant having an activity close to wild type 2A; and the 
JDY4 colony give white colour. 
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The most important conclusion from this study is that the 2A sequence, even the 
non-conserved portion, is largely intolerant to change. Among 200 white colonies (i.e. 
with full 2A activity) analysed by Dr. Sharma, only 8 contained changes to the peptide 
sequence. Moreover, as can be seen in table 3.1, although in general mutations to the 
conserved portion impaired activity to a greater degree, several single alterations within 
the non-conserved N-terminal part also decreased 2A function dramatically (for 
example, mutant N3I only retains a small amount of activity) This was in some degree 
surprising, as the previous alignment study revealed that the N-terminal portion is 
highly variable in different 2A sequences. These results indicated that the importance 
and function of the N-terminal portion of the peptide needs re-evaluation.  
 
Another finding from the random screen was that two of the double mutants identified 
( L1V+L6F and L2W+F4L) had less reduction of 2A activity than mutants containing 
only one of the amino acid changes. In this study, the mutant L2W+F4L conferred white 
colony colour corresponding to a full 2A activity, however, F4L displayed only partial 
activity (pink colony) in the in vivo assay. Similarly, cells transformed with the reporter 
containing the L6F mutation developed a darker pink colour than those containing the 
L1V+L6F 2A variant, indicating a higher activity in the double mutant. As in both cases, 
the other single mutant (L2W and L1V) was not isolated and the activity of them is 
unknown, the basis of the relatively high activity of the double mutants is not known. 
One explanation of this result is that 2 mutants might complement to each other, which 
is interesting and, if confirmed, might be very helpful in extending our understanding of 
the 2A reaction mechanism. 
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3.3 Generation of further mutations within 2A 
 
While the random mutagenesis screen was very revealing, it had some limitations. The 
most significant of these was that, at several positions, few or no mutants were isolated. 
For filling the ‘holes’ left as well as expanding the finding of the mutagenesis screen, a 
number of further single mutants were generated using a site-specific mutagenesis 
strategy, and examined in vivo and/or in vitro. The main limitations of the random 
screen and the mutants designed in the present study to supplement them are listed as 
below: 
   
While the 2 mutations identified at the final position 19 had very little activity, (P19T 
and P19L, see Table 3.2) consistent with the previous study suggesting Pro19 crucial for 
the function of 2A sequence, the limited number of mutations to the 19th position 
limited the strength of this argument. Therefore, a larger collection of amino acid, 
comprising A,E,G,K,R, were introduced at 19th position to replace the proline, to test 
whether or not other amino acids can function at this position.  
 
Alterations to Ser15 showed relatively high activity, with the exception of substitution 
with Tyr. As position 15 of 2A is one of only 2 within the C-terminal region that is 
variable, these data suggest that this is not an important amino acid in terms of 
mechanism. For determining whether a broad or limited range of amino acids at this 
position is compatible with full 2A function, here Ser15 was further replaced with 
A,E,F,G,T,P and I at this position. 
  
The other position that is variable within the C-terminal portion of 2A is amino acid 13, 
valine in the FMDV peptide, though this only extends to Valine and Isoleucine. No 
mutations were recovered at this position in the random screen, and similarly no 
changes to Gly11 were isolated. To generate a more complete picture of the effects of 
mutation of 2A sequence on its efficiency, in the present study, a set of amino acids 
were substituted for Gly or Val at these positions (A,E,F,G,K,L,P to Val13 and A, H, K, 
P to Gly11).  
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In addition to the mutants above, several were made specifically to test the possibility 
that double mutants isolated in the screen had more activity than single mutants from 
which they were composed. 
 
 
3.3.1 in vivo test  
 
The above mutants were inserted into the Ubi-R-2A-ADE2 reporter and transformed 
into the yeast strain Y4 for in vivo assay, as described in section 3.1.3 and 3.1.1. After 
selection for the plasmids on media lacking tryptophan, colonies of each mutant were 
isolated and spotted onto plates containing a limited amount of adenine (40% of the 
normal amount; Figure 3.5).   
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Figure 3.5 in vivo assay for the mutants listed in section 3.3. See text for detail. 
(Mutants G18R and G18P are not relative to the experiment, only occasionally appears 
in the certain experiment represent in the figure) 
 
 
 
Examination of the double mutants (L1V+L6F and L2W+F4L) confirmed the previous 
observation that they have high activity, with L2W+F4L having similar activity to wild 
type. Comparison with 2A variants containing the single amino acid changes that 
comprise the double mutants (L2W, F4L and L1V, L6F) revealed that these also had 
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high levels of activity. Specifically, both of L2W and F4L appeared to have similar 
activity to the combined mutant (L2W+F4L). Therefore whether the high activity of 
L2W+F4L is due to neutral effects or co-operative effect of the 2 single changes need 
further assay to address (see below). On the other hand, L1V+L6F was less functional 
than L1V, and therefore the high activity this double mutant presented was largely due 
to the neutral effects of the 2 single changes rather than any co-operative effect. 
 
The sequences of known 2A peptides suggest that the position 13 and 15 are not 
completely conserved. While 13th position is found only with valine or isoleucine,  the 
15th is more variable with quite a few different amino acids found naturally. This 
difference in conservation was reflected in the present mutagenesis study. Replacement 
of Val13 with any of the amino acids used here, including other hydrophobic amino 
acids (Leucine and phenylalanine) resulted in significant loss of 2A activity.  In 
contrast, the effects of substituting Ser15 varied depending on the amino acid inserted. 
There was though clearly more flexibility at position 15 as none of the substitutions 
completely inactivated 2A, while others (such as serine, proline or alanine) had little, if 
any effect. This contrasted with the Tyr15 mutant isolated in the random screen which 
abrogates 2A activity.  
 
While the majority of alterations at position 19 inactivated 2A, strikingly, mutant P19K 
retained some 2A function. Another mutant, P19A, though not always, also presented 
2A activity in the majority of the experiments (however not in the experiment shown in 
figure 3.5). These results were significant in that previously Proline at position 19 had 
been considered to be necessary for 2A activity. Because the pigmentation of the 
colonies expressing these mutants was hard to quantify, being only slightly less dark 
than those with other mutations to P19, a further study using in vitro assay was needed 
to quantify it exactly (see below).  
 
The substitution of Gly11 for any of the amino acids tested caused dramatic reduction of 
2A function. This included histidine which is the second most common amino acid that 
is found in this position in known 2A peptides. Position 11 is the first conserved 
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position in 2A, and it may provide a ‘link’ between the N-terminal non-conserved, and 
C-terminal conserved portions of the peptide, a more specific analysis on this position 
was carried out below (see Chapter 5).  
 
In general, the in vivo test described in this section was a good complimentary study to 
Dr. Sharma’s random screen, providing several interesting start points for further 
research. 
 
 
3.3.2 in vitro test 
 
As mentioned at last section, quantitative and more precise analysis was required for 
study of several interesting mutants. Therefore, the in vitro assay was performed with a 
set of mutants that included 2 double mutants (L2W+F4L, L1V+L6F) and their 
separated individual mutants, as well as P19K, P19A.  
 
The total eight resulting mutants were inserted into the plasmid pLH135 and 
experiments were performed as described in section 3.2.3 and 3.2.2. Representative 
experiments and the quantitative result were presented in figure 3.6 and table 3.3 
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Figure 3.6: in vitro assay for the mutants listed in section 3.3.2 see text for detail  
 
 
 
Mutants 
Activity by in vitro 
assay 
Colony colour 
in vivo assay 
Wild type 70.8%+/-4.2% White 
F4L 61.2%+/-1.1% White 
L2W 94.4%+/-0.9% White 
F4L+L2W 79.5%+/-0.6% White 
L1V 67.2%+/-2.0% White 
L6F 22.7%+/-5.9% Pink (light) 
L1V+L6F 22.5%+/-6.5% Pink (light) 
P19A 4.5%+/-1.8% Red (variable) 
P19K 6.1%+/-1.1% Pink (deep) 
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Table 3.3  Quantification of the in vitro assay. The experiments were performed and 
quantified as described in section 3.2.3 and 3.2.2. For one mutant three independent 
assays were applied, the results were summarized in column 2 ‘Activity by in vitro 
assay’, in ‘average value +/- standard deviation’ form. The result of in vivo assay of 
these mutants obtained in last section were also listed for comparing, in column 3 
‘Colony colour in vivo assay’ 
 
 
 
 
Results obtained in the in vitro experiments were consistent with those generated with 
the in vivo reporter. The mutants conferring white colonies in in vivo test yielded high 
activity in in vitro analysis, whereas those that grew as red/pink colonies had low 
efficiency in the in vitro reporter.  
 
In this in vitro assay, the double mutant L2W+F4L and the two single mutants that 
comprise it presented high activities. L2W gave 94.4%+/-0.9% efficiency, which was 
higher than that of wild type FMDV 2A (70.8%+/-4.2%), and was the highest 2A 
activity in whole study described in this thesis. The strong activity of L2W+F4L 
(79.5%+/-0.6%) was then not due to two mutant that individually reduce 2A activity 
complementing each other, but more likely attributed to the positive effect of the L2W 
mutant somehwat compensating for the relatively low activity of F4L with a relatively 
lower activity at 61.2%+/-1.1%. 
 
For double mutant L1V+L6F, the in vitro assay confirmed the conclusion of in vivo test: 
the quantification data clearly showed L1V (67.2%+/-2.0%) single mutant having same 
level of activity as wild type 2A, the relative high level of the double mutant L1V+L6F 
(22.5%+/-6.5%) should mainly attribute to the fact that replacement of Leu to Val at the 
first position has little effect on its activity.  
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Two single mutations at Pro19 found to have a low level of activity in the in vivo 
reporter were also active in the in vitro experiments (Figure 3.5b showed the faint but 
clear bands of the up-and down-stream products) Quantification yielded 7% and 6% 
activity for P19A and P19K respectively. These results were consistent with previous 
theory of the importance of Pro19, though these data indicate that it is possible for the 
2A reaction to proceed, albeit at low efficiency, with amino acids other than Proline at 
this position. 
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3.4 Summary and discussion 
 
Site-specific mutagenesis study presented in this chapter is a good complimentary study 
of the previous random mutagenesis study. The analysis of Val13 and Gly11 filled the 
‘holes’ of the random screen. The result of the analysis, combined with Dr Pamila 
Sharma’s results, suggest the whole 19 amino acid in 2A sequence is more intolerant to 
mutation than expectation. Alteration at any of the 19 positions changes (mostly impairs) 
the 2A function. Thus, 2A is unlike some other short peptides, the whole 2A sequence is 
important and every amino acid contributes the function in some way.  
 
Substitutions of glycine to histidine at position 11 caused dramatic loss of 2A activity. 
This result is slightly unexpected, as histidine is the second most frequent amino acid 
that is found at this position in identified 2A peptides. Since histidine at position 11 
functions well in other 2A sequences, such as the one from TMEV (Donnelly et al., 
2001), given the high conservation of the C-terminal motif, the element(s) that 
determine the functional amino acid at position 11 is mostly likely contained within the 
variable N-terminal portion, i.e position 1-10. The potential relationship between 
position 11 and N-terminal portion will be discussed in more details in chapter 5. 
 
Valine and Isoleucine are the only two amino acids that are found at position 13. As this 
two amino acids share the properties of strong hydropathy and the branched side chain, 
these features were thought as the requirements of the amino acids at this position. 
However, present study revealed that, the substitution of the hydrophobic and/or 
branched side chain comprised amino acids (leucine, alanine, phenylanine and glutamic 
acid) displaced no different activity from these with other amino acids (proline, glycine, 
lysine): none of the mutation at position 13 tested in this study resulted in a significant 
activity. Although the mutations tested here is not an exhaustive set, this result suggests 
a more strict requirement at this position for a functional sequence.  
 
In contrast to position 13, the position 15 of 2A sequence is more variable in known 2A 
peptides. Intriguingly, it was observed in previous random screen that, tryptophan 
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replacement at this position nearly inactivated the function of the peptide. (table 3.1 
S15I) Therefore, the question arose as whether a broad or limited range of amino acids 
at this position is compatible with full 2A function, and to answer this question, Ser15 
was further mutated with the replacements of A,E,F,G,T,P and I at this position. The 
result, though varied depending on the amino acid inserted, in general suggested a more 
flexible requirement at this position, as none of the mutants tested, except S15F that 
resulted in a medium level of function, induced a substantial impairment of the activity. 
The reason why tryptophan not allowed at position 15 requires further analysis to 
reveal. 
 
Pro19 at the end of 2A is considered indispensable for 2A function. However, the 
present study revealed that mutant 2A sequence with other amino acids in this position 
still function in at a minor level. This result is consistent with an old study showing that 
TMEV 2A tolerates some substitution at Pro19 (Hahn et al., 1997). This implies that the 
mechanism of 2A is more complex than thought.  
 
In previous study, two double mutants were noted because that their activities are more 
than one of the single mutants alone. Present project generated all of their single 
mutants and tested them with more precise assay. It was revealed that the strong activity 
of double mutants is more likely contributed by their other single mutants along, rather 
than the interaction within 2A sequence or compensation effects of two mutants. 
 
In summary, the present site-specific mutagenesis study answers the several questions 
left by previous random screen study, and confirms the main finding of previous study: 
that the 2A sequence is NOT as flexible as one might imagine, particularly given the 
variability with in the N-terminus of the peptide. 
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 Chapter 4: Systematic substitution of each FMDV 2A position 
 
 
 
This chapter describes a systematic scanning mutagenesis of 2A. Each amino acid of 
FMDV 2A was individually replaced by alanine, proline or glycine and the activity of 
the mutants were assessed by in vitro and in vivo (partly) assay. There were two 
aims/reasons for this: the first is that it was a complementary approach to the previous 
random screen. The random screen combined with site-specific mutagenesis analysis 
described in chapter 3 had revealed that the mutations at every position of the sequence 
affected its 2A efficiency. However, while comparing the tolerance for mutation of 
different positions, the various properties of different amino acids substituting at 
different positions might affect the conclusion. Thus, analysis of a set of 2A mutants in 
which each position was substituted by a same amino acid could provide a new angle to 
examine the general trend of the effect of altering each position within the peptide. The 
second aim was to test the importance of secondary structure in 2A function. In previous 
studies, it was observed that more than half of 2A sequences identified, including the 
one from FMDV, have a strong α-helical propensity in their N-terminal portion, or 
indeed much of the whole sequence (Ryan et al., 1999). Since three amino acids 
selected for the scanning analysis, alanine, glycine and proline have distinct influences 
on secondary structure, comparing the difference in effects of these amino acids was 
helpful to assess the significance of α-helical propensity.  
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4.1 Analysis of 2A sequences: secondary structure propensities 
 
More than half of 2A sequences identified, especially these from picornavirus, have 
been suggested to adopt an α-helical conformation within the ribosomal exit tunnel over 
much of their sequence. In general, the most likely conformation of an amino acids 
chain inside the exit tunnel is α-helical (Nissen et al., 2000). All of the amino acids of 
the N-terminal part of these 2A peptides are favourable to form an α-helical structure; 
and on an earlier study (Ryan et al., 1994) using molecular dynamics modeling it was 
found that, the whole sequence of FMDV 2A except two final amino acids may adopt an 
α-helical conformation with a reverse turn at the C-terminal end. 
     
As mentioned in the introduction, the 2A reaction is a co-translational event. When the 
event occurs, the two final codons of 2A, proline and glycine are in the A and P site of 
ribosome respectively, with the rest of the 2A peptide within the ribosomal exit tunnel. 
Abundant evidence suggests that newly-synthesized polypeptides are able to form 
secondary structure or even ternary structure (Kosolapov et al., 2009) within the tunnel. 
Indeed, forming a secondary structure inside the exit tunnel is not an unusual strategy 
for the peptides manipulating the translation procedure. During the SecM- or 
AAP-induced translation stall, the peptide inside exit tunnel is in a compact, likely 
helical form (See section 1.2.4.1) (Woolhead et al., 2006; Bhushan et al., 2010). 
Therefore, it is possible that during the 2A reaction, the growing amino acids chain of 
2A adopts an α-helix conformation inside ribosome, with two final codons at the 
peptidyl tranferase centre. One of the aims of the study described in this chapter is to 
examine the roles and importance of this potential structure to the 2A event. For this 
purpose, three amino acids with distinct impact on α-helical conformation were selected 
for the systematic scanning, namely proline, glycine and alanine. 
 
Glycine is one of most unfavorable amino acids to form the α-helix and proline is 
unable to adopt the correct conformation to ‘fit’ into an α-helix; indeed examination of 
known structures reveals that they have two lowest frequency of occurrence in α-helical 
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conformation (Figure 4.1b). These two amino acids obtain their ‘helix breaker’ feature 
by distinct mechanisms: proline has a unique, cyclic side chain (proline ring) that 
connects with the peptide backbone twice (Figure 4.1a). This constrains the 
confomrations that the backbone can take and prevents the formation of α-helix. In 
contrast a peptide backbone containing glycine, without a side chain, is easily reduced 
to coil. Alanine, with a non-polar (–CH3) side chain has a high frequency of occurence 
in α-helices and insertion of alanine in place of other amino acids typically does not 
disturb an existing helix (Figure 4.1b). Due to these different properties, it might be 
expected that the effects of the substitution of individual amino acids of 2A with proline, 
glycine and alanine may be different, and the significance of α-helical propensity can be 
addressed by this variability.    
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Figure 4.1 distinct α-helical propensities of glycine, proline and alanine.  
 
(a) Chemical structure formula of the three amino acids. The different side chains 
should be noted. (Taken from “Lehninger principles of biochemistry”)  
(b) α-helical propensity scales of amino acid, by different methods. Exptl, AK/AQ (Rohl 
et al., 1996), based on the data from helix-to-coil equilibrium experiments; AGADIR 
(Munoz et al., 1995), by the data from peptides; Williams (Williams et al., 1987), C&F 
(Chou et al., 1978),  based on the frequency of occurrence of amino acids in a-helices 
in proteins; luque (Luque et al., 1996 ) based on the structure biology study. The data 
presented as D(DG) values relative to Alanine, which has been set to zero because it is 
usually the amino acid with the most favourable helix propensity. Proline is not in the 
scale due to its extreme non-preference to the α-helical structure (reproduced from 
(Pace et al., 1998). 
 
 
 
4.2 Scanning mutagenesis of FMDV 2A and in vitro analysis 
 
To accurately assess and compare the 2A function of different mutants, the 2A activities 
of the variants in this scanning study were mainly assessed with the [CFP-2A/2A*-PAC] 
reporter and in vitro test. 47 target mutants, comprising 18 mutants in which each amino 
acid of FMDV 2A was individually replaced by alanine, 17 that of proline and 13 
glycine mutants, were generated by the site-specific PCR using the primers specifying 
the desired change, as described in section 3.2.3.  
 
The other four glycine mutants, namely D5G, L6G, A10G, E14G, were obtained by 
different approach. These mutants were isolated in Dr Pamila Sharma’s random 
mutagenesis study, (section 3.1) therefore they could be obtained from the collection of 
PCR fragments used to identify the mutant in previous study. For exploiting these 
fragments, a pair of primers (Methods and Materials Ubiq5 and AD3 in table 2.3) that 
complemented the flanks of these fragments was used to amplify them from the existing 
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constructs (Method and Materials section 2.4.3).  
 
The 52 PCR products corresponding to the unique 2A mutants were then inserted into 
plasmid pLH135 plasmid using XbaI and ApaI restriction sites, replacing the wild type 
2A coding sequence of the [CFP-2A-PAC] reporter with the mutant ones. The resulting 
plasmids were sequenced by GATC biotech with primer 135SEQ, to conform the 
present of desired mutations, as well as no undesired mutations introduced during the 
procedures.  
 
The sets of mutants were then used in coupled in vitro transcription/translation assays, 
as described in section 3.1.2. Representative gels for the glycine, proline and alanine 
series of mutants (a) and quantification data of the assay (b,c) result are shown in Figure 
4.2-4.4.  
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Figure 4.2  Activities of [CFP-2A-PAC] variants containing Alanine substituted for the 
individual amino acids of 2A indicated, and the wild-type (WT). See text for details. 
a. A representive in vitro assay of the whole set of alanine substituted 2A mutants. E, up 
and down refer to the complete (extended) translation product [CFP-2A-PAC], and the 
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upstream [CFP-2A] and downstream [PAC] products of the 2A reaction, respectively.  
 
b. Three independent sets of experiments as in a. were quantified for each set of 
substitutions. Average activity (% of ribosomes releasing the upstream product) ± one 
standard deviation is shown. 
 
c. Same as that in b., but 2A activity was seted as their ratio to the acitvity of wild type 
2A. 
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Figure 4.3 Activities of [CFP-2A-PAC] variants containing Glycine substituted for the 
individual amino acids of 2A indicated, and the wild-type (WT). See text for details. 
Figure 4.3 a,b,c are in the same form as Figure 4.2.  
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Figure 4.4 Activities of [CFP-2A-PAC] variants containing Proline substituted for the 
individual amino acids of 2A indicated, and the wild-type (WT). See text for details. 
Figure 4.4 a,b,c are in the same form as Figure 4.2 
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Individual replacement of each amino acid of the 2A peptide with glycine, proline or 
alanine led, in general, to impaired activity. Out of a total of 52 unique mutants tested in 
this scanning study, only three substitutions, L1P, L1G and L2A, that were neutral; and 
four, L2P, L1A, L2G, and S15P which resultsed in only minor loss of the activity. The 
rest 45 mutants suffered significant loss of the activity, and 6 of 7 of these exceptions 
occurred in Leu1 and Leu2. Hence, this result was consistent with the conclusion of 
previous studies based on random screen, that whole sequence of 2A peptide is largely 
intolerant to mutagenesis. 
 
 
The effects of altering each position to glycine, proline, and alanine are generally 
similar. In most cases, substitutions to amino acids more C-terminal within 2A had more 
deleterious effect than changes to those within the N-terminal part, with a main 
exception of position 15. While general trends were consistent with the previous 
alignment study suggesting the conserved C-terminal and variable N-terminal portion 
(Donnelly et al., 1997), this result was unexpected to the distinct properties of glycine, 
proline, and alanine, as mentioned above. Given these differences of the three amino 
acids, especially in term of how they influence the conformation of the nascent chain, 
the data obtained argue against specific secondary structure of a large part of 2A 
(especially the N-terminal portion) being necessary and sufficient for the 2A reaction. In 
particular, since substitutions to alanine had similar effects to glycine and proline the 
data argue against an α-helical conformation being sufficient. Therefore, the similarity 
of effects of their substitutions could only be explained that, the α-helical propensity or 
potential α-helix structure alone could not satisfy the requirement(s) for 2A function, 
there must be other factors such as side chain involved. 
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Figure 4.5 Comparison of three amino acid scanning. At each position, the 2A activity 
(ratio to the wild type) of mutants containing proline, alanine and glycine are 
summarized from Figure 4.2c, 4.3c and 4.4c.  
 
 
Although the general patterns of Glycine, Proline and Alanine were similar, indeed they 
gave some minor differences: on the whole, at some position, substitution with Proline 
cause a more several reduction of 2A activity than the other two, with the exception of 
position 15. Moreover, several differences were observed at some certain positions. At 
positions 4-5, alanine substitutions showed relatively considerable 2A activities (F4A 
55% and D5G 59% as wild type). This had a minor edge to the glycine series (F4G:42% 
D5G:28%) and a pronounced advantage to proline series (F4P:21% D5P:9%) at the 
same positions. Therefore, while the α-helical propensity might not be that critical for 
the most of the length of 2A peptide, it might be required in this region of the sequence. 
However, the amino acids at these positions in wild type FMDV, phenylalanine and 
aspartic acid, are the two of only three amino acids within the N-terminal portion that 
are relatively unfavourable to the helix. This fact discounts the above argument. A more 
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promising difference was shown at position 8, where the alanine mutant displaced 
pronounced to both glycine and proline ones. Another position that showed obviously 
different effect was position 15, the only position that was highly variable in the 
C-terminal motif. At this position 15, it was the glycine replacement S15G that resulted 
in the lowest function (only 25%). The activity of S15P and S15A were 90% and 65% 
respectively. The substitution of glycine impaired the function more severely than that 
of others. This might be due to the detrimental flexibility of the peptide backbone 
introduced by glycine, or another possibility of the 15th position’s requirement for side 
chain size of amino acid.           
 
 
 
 
4.3 In vivo examination of scanning mutants of FMDV 2A 
 
The in vivo analysis of scanning mutants of 2A was a supplementary study to the in 
vitro scanning described in section 4.2. The main aim of these experiments was to check 
whether the conclusions of the in vitro scanning were independent of the organism and 
the method used. In in vivo scanning, PCR fragments containing 26 different mutants, 
including the whole glycine series and 9 proline mutants (at position 
1,2,4,7,10,11,13,15,18) were selected from the same collection of 52 PCR products used 
in in vitro study, and placed into the in vivo reporter [UBI-R2A-ADE2] plasmid 
pJNY58, by NcoI and BamHI sites. The resulting plasmids were sequenced with primer 
AD3 for conforming, and then transferred into yeast strain JDY4 for in vivo assay, as 
described in section 3.1. Results of a typical experiment is presented in Figure 4.6 
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Figure 4.6 in vivo assay of whole glycine series and part of proline series. See text for 
details. My data, figure reproduced from Sharma et al., (2012). 
 
 
All mutants tested in this experiment yielded comparable results to those obtained in 
vitro. The full set of glycine substitution presented the same general trend as the in vitro 
assay, as did the selected proline mutants. These results confirmed that the functions of 
the 2A mutants showed in last section were irrelevant to the constructed used (pLH135 
or pJNY58), method tested (in vitro or in vivo) and organism based on (mammal or 
yeast).     
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This result was the other evident that the in vivo and in vitro assay we used in this study 
complemented to each other. 
 
 
 
 
4.4 Summary and Discussion 
 
In the research described in this chapter, systematic substitutions were applied to the 2A 
sequence from FMDV with three different amino acids glycine, proline and alanine. The 
full sets of mutants of glycine, proline and alanine series were examined with in vitro 
assay; and whole series of glycine as well as 7 proline mutants were also tested with in 
vivo reporter system.   
 
With the in vitro test, all three amino acids tested presented generally similar effects at 
each position of 2A position. In general, the closer, a position is to the C-terminal end, 
the more serious impairment that results from the substitution, with a major exception 
of position 15, at which the substitutions with proline and alanine retain considerable 
activity, and substitution with glycine showed a low level activity, but higher than that 
of glycine substitutions at surrounding positions. These results, combined with the 
studies based on random screen, suggests that this trend reflects general sensitivity of 
the positions of 2A to the mutations, regardless of different amino acids substituting, 
which, in turn, implies the significance of the amino acids located at these positions: 
while every amino acids of the whole 2A sequence contributes to the function, the 
contribution of those near the C-terminal end is more critical than that of N-terminal for 
2A function. This, once again, coincides with previous 2A alignment study (Donnelly et 
al., 1997). 
 
As the three amino acids selected here have distinct effects on secondary structure, the 
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similarity observed from the mutants of glycine, proline and alanine was unexpected. 
Due to alanine substitutions (that are favorable to the α-helical conformation) failed to 
show significant ‘edge’ over that of helix breaker proline and glycine at most of the 
sequence, the α-helical propensity previously thought critical for the 2A function might 
not be crucial, or at least that the structure of the backbone alone could not satisfy the 
requirement(s) of 2A function at most positions, other factors such as side chain must be 
considered. 
 
As discussed in introduction, the structures of other peptides driving the ribosome vary: 
for example, the TnaC adopt an extended conformation inside the ribosomal exit tunnel 
(Seidelt et al., 2009), and the arginine attenuator peptide is in a compact form. Hence, 
the potential conformation of 2A peptide adopted within the ribosomal exit tunnel and 
its contribution to the 2A function needs further research. 
 
The 15th position of the 2A sequence is the only position that is highly variable in the 
C-terminal motif. In the present scanning study, position 15 gave the greatest variation 
in different amino acid substitutions: S15G showed far less 2A function than S15P or 
S15A.  A possible explanation for this might be that the flexibility introduced into the 
peptide backbone of 2A by glycine is unfavorable in this position. But after review of 
all the mutants tested in Dr. Pamila Sharma’s random screen (see section 3.2) and the 
study described in this thesis (see section 3.3), an alternative requirement emerges. Of 
ten mutants occurred at position 15, amino acids with a similar sized side chain 
(molecular weight ranging 30 g/mol to 50 g/mol) caused the least effect on 2A activity, 
and it seems like that the more MW of side chain deviated from this range, the more 
serious impairment of the 2A function the amino acid substitution suffered. Indeed, 
while mutants containing proline, cysteine or threonine at 15th position exhibited 
similar high activity to wild type, alanine at this position (small side chain) yielded 
compromised activity; and tyrosine, with the bulkiest side chain, decreased 2A function 
dramatically. Therefore, there might be a requirement of the size of side chain for the 
position 15 of FMDV 2A. 
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Finally, the in vivo test based on yeast genetic method was performed to the selected 
mutants of the in vitro scanning. The results of these two tests were consistent with each 
other, proving that these data were independent to the construct, organism and the 
method used.  
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Chapter 5: Combination mutants of different type of 2A sequences 
 
 
    
The 11th position of 2A sequence is the first amino acid that is conserved. In all 2A 
peptides that have been identified, glycine is the most common amino acid at this position. 
80.6% of 2A sequences, including the one from FMDV, have glycine at position 11. The 
second most common amino acid at position 11 is histidine, which 14.5% of 2A 
sequences contain. Interestingly, site-specific mutagenesis revealed that, a histidine 
replacement to the position 11 of the FMDV 2A caused nearly total loss of its activity 
(section 3.3). Moreover, when comparing different 2A peptide it was observed that, the 
2A sequences with Gly11 and these with His11 had distinct preferences for the amino 
acid found within the N-terminal ‘non-conserved’ region.  Therefore, according to the 
amino acid at 11th position, 2A peptides can be classified into two types: Gly11 type and 
His11 type. As two types of 2A sequence appear to have very different constraints within 
the N-terminal portion, there may be some amino acids or combination of amino acids 
among N-terminal portion that interact with the amino acid at position 11. For identifying 
these potential functional units of N-terminal portion, two approaches were applied in the 
study described in this chapter. Firstly, the N-terminal half and C-terminal half (including 
position 11) from different type of 2A sequences were fused, to check whether they could 
function with each other; secondly, several ‘snippets’ (amino acids or combinations of 
amino acids), were picked from the His11 type 2A sequence, then fused into the 
corresponding positions of the FMDV mutant G11H. If a small portion of the H11-type 
2A could restore activity within the G11H mutant of FMDV, this would delimit the 
interacting parts of the peptide.  
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5.1 Different type of 2A sequence present distinct constraints at ‘non-conserved’ 
positions 
 
To aid in interpretation of mutagenesis data, an extensive alignment study was performed 
with 2A peptides from different viruses. During the period of the present study, our 
laboratory examined the full set (at that time) of identified 2A peptides (52 individual 
ones) (Sharma et al., 2012). Since then, several more 2A sequences have been discovered. 
Thus, here an updated alignment analysis is presented, with the same approach as the 
published data but a new collection of 2A peptides that is showed in (Table 5.1).  
 
 
Organism Sequence 
Ljungan virus 145SL YSGGKFLNQCGDVESNPGP 
Porcine teschovirus ATNFSLLRQAGDIEENPGP 
Human cosavirus QVARMLLQISGDVESNPGP 
Theiler's encephalomyelitis virus HADYYKQRLIHDVETNPGP 
BHuV-1/OHuV-1 ATNFSLLRLAGDVELNPGP 
SPaV-1 EELQNMILQCGDVEQNPGP 
RaPV-1 GYRGDLLMQAGDVESNPGP 
BRAV-2 VSNKDLLLQAGDVETNPGP 
MsPV-1 MEDHSDILLGGDVEENPGP 
Branchiostoma floridae VISQLMLKLAGDVEENPGP 
 
 
Table 5.1 The 2A peptides identified since August of 2011. To identify the new 2A 
peptides, the sequence information of virus updated within the year (form databases 
‘Picornaviurs home’ (www.picornaviridae.com) and NCBI nucleotide 
collection/non-redundant protein sequences) was searched by the 2A C-terminal motif, 
then the resulting sequences were compared with the existing set of 2As to remove the 
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redundant ones. Finally ten putative new 2A sequences were identified and added into the 
existing collection of 2A peptides. 
The updated 2A collection of total 62 (52 published in Sharma et al., (2012), plus 10 
identified since 2011) unique 2A sequences as well as its two subsets, that of the 
sequences having glycine (of 50 sequences) or histidine (of 9 sequences) at position 11, 
were analyzed and represented by weblogos program 
(http://weblogo.berkeley.edu/logo.cgi), and the result of the analysis was displayed in 
Figure 5.1 
 
 
 
A  
 
B 
 
C 
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Figure 5.1 Conservation within 2A peptides is shown as Weblogo representations. Each 
stack of letters corresponds to one position within the sequence,with the height of each 
stack indicating the conservation at that position and the height of letters within the 
stack the frequency at which the corresponding amino acid is found.  
 
Separate Weblogos are shown for (A) the full set of 62 2A peptides (B) 2A peptides 
with Gly at position 11 (50 sequences) and (C) 2A peptides with His at position 11 (9 
sequences). 
 
 
 
 
As expected, the result of the new 2A collection was largely consistent with the original 
published one. Beside the C-terminal DV(I)EXNPGP motif, position 11 also displayed 
high conservation. Glycine was presented at this position in 50 of the 62 distinct 
sequences, and histidine in all but three of the rest, and the sequences with Gly11 and 
His11 displayed distinctly different amino acids in the N-terminal region as well as at 
position 15. In positions 6-9, leucine was the most common amino acid with Gly11, but 
comparably rare with His11, except position 9. Isoleucine is the most frequently found 
amino acid at 10th position of His11 type but is not seen in this position of Gly11 
sequences. At the highly variable 15th position His11 2A peptides largely contained 
threonine or methionine, of which the latter never present in sequences that contain Gly11. 
These result, together with the finding that the substitution of glycine to histidine at 
position 11 of FMDV caused almost complete loss of activity (section 3.3), proposed the 
possibility there was co-operation(s) between amino acid at position 11 and these at the 
variable positions, and Gly11 and His11 held respective requirement over these amino 
acids.   
 
Since these outcomes highlighted the significance of G11H mutant, here I tested this 
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mutant with in vitro assay to get the precise activity. The assay was performed with the 
method described in section 3.1, using the construct pLH135 built with the G11H 
containing PCR fragment. As expected from in vivo test, a very limited activity (9.1%) 
was found. (shown in Figure 5.3)    
  
 
5.2 Fusion of two type of 2A sequence  
 
 To identify the non-conserved positions that co-operated with position 11, a set of 2A 
fusion sequences were made. Here, two sequences of His11 type of 2A, which were from 
Encephalomyocarditis Virus (EMCV) and Theiler's murine encephalomyelitis virus 
(TMEV), were chosen and combined with the sequence of  FMDV 2A, which was of 
Gly11 type. These fusion mutants were placed into the pLH135 plasmid, and the result of 
in vitro assays using these is presented in this section.  
 
5.2.1 EMCV and TMEV 2A sequences function with the in vitro reporter system 
 
 The 2A sequences of EMCV and TMEV presented high levels of 2A activity (102% and 
77% when compared to FMDV 2A) in previous research using reporter construct 
[GFP-2A-GUS] and in vitro transcription/translation assay with wheat germ extract 
(Donnelly et al., 1997). Here, we tested their function with the in vitro reporter system 
used in present study, the construct [CFP-2A/2A mutant-PAC] (pLH135) and coupled in 
vitro translation with rabbit reticulocyte lysate, to check whether they function with the 
system used in present project. 
 
Due to the considerable variances between 2A sequences of EMCV, TMEV and FMDV, 
the strategy used to replace the wild type FMDV 2A with target sequence was different 
from that described in section 3.2 (see Figure 5.2). Here, for each sequence, two 
complementary oligonucleotides were designed that, after annealing, generated a 
fragment that coded for the desired 2A peptide, and also had 5’ overhangs complementary 
to XbaI and ApaI sites at the 5’ and 3’ end of the fragments. These were then ligated into 
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pLH135 digested with XbaI and ApaI. The resulting plasmids were sequenced to confirm 
that they had the correct, and were then tested by coupled in vitro translation with rabbit 
reticulocyte lysate.  
 
 
 
 
Figure 5.2  The clone method for the generation of mutants and assembling of pLH135 
variants. Two oligoes containing the complimentary coding region that compose the 
target sequence and overhangs that compose two ‘fake’ restrict sites were designed. 
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After annealing as protocol in section 2.4.5, the resulting fragment was ligated to the 
enzymes digested vector pLH135.  
 
 
 
 
 
The result of in vitro assay for EMCV and TMEV is shown in Figure 5.3. Quantification 
of this and similar gels is presented in Table 5.2 (Activity-present).  
 
 
 
Figure 5.3 Representive experiment of in vitro assay for TMEV, TMCV and FMDV. 
Plasmids encoding [CFP-2A-PAC] reporter containing the indicated 2A sequence were 
used in coupled in vitro transcription/tranlsation assays, and resolved on a SDS-PAGE 
gel. Migration of markers run alongside are indicated.The assays were performed with 
the same protocol described in section 3.1.2, chapter 3.  
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2A species Activity-present Activity-previous 
TMEV 60.66% +/- 6.80%          65% 
FMDV 70.04% +/- 0.74%          90% 
EMCV 92.84% +/- 1.87%          91% 
 
 
Table 5.2 Quantified activities of in vitro assay for TMEV, TMCV and FMDV. For each 
2A sequence, the average activity and standard deviation of 3 experiments was listed in 
column ‘Activity-present’; and previous quantified data obeserved in (Donnelly et al., 
1997) were listed in ‘Activity-previous’ for comparison. 
 
 
The 2A from EMCV and TMEV were active, in the system of present study, and 
particularly, the quantification data obtained here were comparable to the data of the 
previous study. (Donnelly et al., 1997)  Due to different methods and quantification 
formulas used the specific values of the two studies were not identical, but the relative 
activities were consistent to each other. (Table 5.2) It was concluded that 2A peptides 
form EMCV and TMEV were functional in the in vitro system used in present project, 
and were then a good start point for the study of the requirements for H11- and G11-type 
2A peptides to function. 
 
 
5.2.2 Fusion mutants of EMCV, TMEV and FMDV of 2A sequences are largely 
inactive. 
 
 
To examine potenital link(s) between the N-terminal portion and C-terminal motif of 2A, 
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and particularly the amino acid at position 11,  five fusion mutants of the N-terminal half 
and C-terminal half from different 2As were made. The fusion mutant was named after 
the first letter and the number of amino acids of two 2A sequences fusing it. For 
example, ‘10T+9F’ mean a mutant fused by the first 10 amino acids of TMEV 2A 
peptide and last 9 of that of FMDV. The names and sequences of the five fusion mutants 
analysed in present study are shown in table 5.2. The approach described in section 5.2.1 
was used to generate these mutants. 
 
Coupled in vitro transcription/translation assays with the constructs bearing the 2A 
fusions revealed (Figure 5.4) that they had limited 2A activities (from 13 to 25% of 
FMDV 2A). Since each of the native 2A peptides functioned well, the initial conclusion 
was that the impairments of activity must be ascribed to failed co-operation(s) between 
the N- and C-terminal halves. Close examination of the differences between native 2A 
peptides and the fusions generated suggests that their may be interaction between position 
11 and 15. Specifically, the fusion T10/11F is equivalent to a H11G/T15S double mutant 
of the TMEV 2A. However, the function of a 2A peptide with histidine at position 11 is 
not entirely due to the presence of threonine (or methionine) at position 15, otherwise the 
fusions of the FMDV N-terminal portion to the C-terminal regions of TMEV or EMCV 
2A would have been expected to function well, which they did not. This this, indicates the 
existence of interaction(s) between glycine/histidine at position 11 and the rest of 2A. 
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Figure 5.4. Representive experiment of in vitro assay for fused 2A mutants. Plasmids 
encoding [CFP-2A-PAC] reporter containing the indicated 2A sequence were used in 
coupled in vitro transcription/tranlsation assays, and resolved on a SDS-PAGE gel. 
Migration of markers run alongside are indicated. Note that the FMDV sample was run 
on the same gel but not alongside the other samples. The assays were performed with 
the same protocol described in section 3.2.2, chapter 3.  
 
 
 
Mutants Sequence Activity 
TMEV HADYYKQRLIHDVETNPGP 60.66%+/-6.83% 
FMDV LLNFDLLKLAGDVESNPGP 70.04%+/-0.74% 
EMCV YAGYFADLLIHDIETNPGP 92.84% +/- 1.87% 
10T+9F HADYYKQRLIGDVESNPGP 11.90%+/-3.27% 
9T+10F HADYYKQRLAGDVESNPGP 9.84% +/-2.68% 
9F+10T LLNFDLLKLIHDVETNPGP 14.48%+/-1.11% 
9F+10E LLNFDLLKLIHDIETNPGP 18.16%+/-4.43% 
9E+10F YAGYFADLLAGDVESNPGP 15.00%+/-2.88% 
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Table 5.3 Sequence and quantified activities of in vitro assay for fused 2A mutants. For 
each 2A mutant, the average activity and standard deviation of 3 experiments are listed 
in column ‘Activity’; the sequences of the fused mutants are presented in column 
‘Sequence’, the sequence of TMEV, FMDV, and EMCV is highlighted with colour blue, 
black, and red respectively.  
 
  
5.2.3 Inserting amino acids from His11 type 2A peptides into the G11H FMDV mutant 
failed to recover 2A function 
 
The results described in the last section suggested that co-operation and communication 
within amino acids of 2A, especially between the glycine/histidine at position 11 and the 
amino acids located in the N-terminal portion of the peptide. However, the particular 
amino acids or combination of amino acids that responded to the position 11 were yet 
identified. For pinpointing this, a variety of changes were made to the G11H FMDV 2A 
mutant. Mutants made are listed in Table 5.4, and reflect the most frequently occurring 
amino acids in H11 type 2A peptides. Mutations were also inserted into the wild type 
(G11) FMDV peptide to test whether they interfered with function. This was an important 
control given that most changes to FMDV 2A affect its function (Chapters 3 and 4). 
 
Positions 4-7 are most commonly YYKQ in H11 type 2A peptides and it was noted that 
these amino acids are rarely found in the same positions in G11 type 2A peptides, and thus 
this stretch of amino acids was considered to be a good candidate for allowing a H11 
peptide to function. Following the same logic (common with His11 but rare with Gly11) 
as above, A10I, and L7D mutants were also examined in the experiments described in this 
section. 
 
The mutants mentioned above were generated as section 3.1, except for YYKQ where the 
method described in section 5.2 was used. After constructing and sequencing, these 
mutants were tested by in vitro assay, of which the quantification data were presented in 
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table 5.4.   
 
 
Mutants Sequence Activity 
G11H LLNFDLLKLAHDVESNPGP 9.1%+/- 2.7% 
A10I LLNFDLLKLIGDVESNPGP 5.5%+/-7.3% 
A10I+G11H LLNFDLLKLIHDVESNPGP 6.2%+/- 2.8% 
L6K LLNFDKLKLAGDVESNPGP 33.2%+/- 2.7% 
L6K+G11H LLNFDKLKLAHDVESNPGP 1.3%+/- 2.2% 
L7Q LLNFDLQKLAGDVESNPGP 2.5%+/- 1.8% 
L7Q+G11H LLNFDLQKLAHDVESNPGP 3.1%+/- 0.9% 
L7D LLNFDLDKLAGDVESNPG 0.9%+/-1.5% 
L7D+G11H LLNFDLDKLAHDVESNPGP 3.1%+/-3.1% 
KQ+G11H LLNFDKQKLAHDVESNPGP 1.2%+/- 2.4% 
YYKQ LLNYYKQKLAHDVESNPGP 0.2%+/- 0.3% 
 
 
Table 5.4  Sequence and quantified activities of in vitro assay for 2A mutants 
mentioned in section 5.2.3. For each 2A mutant, the average activity and standard 
deviation of 3 experiments are listed in column ‘Activity’; the sequences of the fused 
mutants are presented in column ‘Sequence’, the sequence of FMDV and the sequence 
fragment common for the His11 type of 2A is highlighted with colour black and blue 
respectively. 
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The result of the assay showed that none of these mutations, regardless of whether they 
were introduced alone or together with His11, conferred a significant activity except the 
single mutant L6K.These data suggested that the minor alterations were not able to 
compensate the activity loss caused by G11H mutation. This is consistent to the proposal 
that the specific combinations of amino acids throughout the N-terminal portion of 2A 
enable it to function (see discussion). 
 
Another result to be noted was that the fusion 2A mutants described in last section 
presented slight higher activity than the separated mutants here. This suggested that even 
without His11, the patches selected from His11 sequence preformed better with their own 
contexts, which was another proof of the existence of the complex co-operation(s) within 
the N-terminal portion.    
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5.3 Summary and Discussion 
 
The comparison of the full set of available 2A peptides revealed that besides the 
recognised C-terminal motif, position 11 is also conserved. 2A sequences could be 
classed into two types based on the amino acid (glycine or histidine) at the 11th position, 
and sequences of these different types presented distinct amino acids usage at the 
non-conserved N-terminal positions within the peptide. These findings were confirmed 
by a renewed alignment study with updated collection of 2A sequences in present project. 
 
These observations, combined with the mutagenesis data obtained in chapter 3 and 4, 
suggest the existence of co-operation(s) between position 11 and other positions, and 
Gly11 or His11 has the different requirements of these positions, namely position 1 to10, 
and position 15. As H11G/T15S double mutations of TMEV 2A (fusion mutant T10/11F) 
caused dramatic loss of function, the position 15 was supported important to the 2A 
reaction. This view has been supported by the fact that His11 relies (at least in some 
contexts) on T15 (JD Brown, personal communication). The distinct ‘style’ within      
positions 1 to 10, has been confirmed as important for 2A function. 
 
Fused 2A mutants of sequences of different type were made and tested with an in vitro 
assay. The results shows that the N-terminal half (position 1 to 9/10) and C-terminal half 
(position 10/11-19) from different type of 2A sequences could not function together. As 
the major difference of the C-terminal halves of two types of 2A sequence is the amino 
acid at position 11, this result is consistent with our hypothesis that Gly11 and His11 have 
respectively specific requirement(s) over the context within N-terminal half; and in turn, 
certain amino acid(s) or combination of amino acids of N-terminal half have to satisfy 
such requirement(s) by some way(s), to make the Gly11 or His11 functional and hence 
the whole sequence working.  
 
For identifying these amino acid(s) or combination of amino acids that were interactive 
with amino acid at position 11, various ‘snippets’ picked from the N-terminal half of 
His11 type of 2As were introduced into the same position of FMDV 2A, having each with 
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Gly, or His at position 11. However, none of these sequence ‘snippets’ compensated for 
the loss of activity caused by the substitution of the Histidine at position 11. As the chosen 
snippets here covered most critical positions of the N-terminal half, ironically it seemed 
that only a ‘snippet’ including the whole sequence from position 1 to 10 of a His11 
sequence was able to compensate mutant G11H of FMDV 2A, namely, function of 
position 1-11 was integrated.  
 
Since the amino acid or combination of amino acids or the N-terminal half we picked 
from His11 sequences works well in their own context but  do not function in the same 
positions of FMDV, they must fulfil their function (presumably the correct position of the 
C-terminal motif) co-operatively rather than each amino acid individually. Thus, these 
results suggest the whole N-terminal portion up to and including position 11 function as a 
unit, and amino acids within it are optimized to each other through the evolution.  
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Chapter 6: Analysis of proline 19 to stop 2A mutants-directed 
ribosome-nascent chain complex (19X RNC) 
 
 
According to the model of 2A reaction discussed in introduction (Figure 1.5) the first 
two steps of the reaction promote translation termination at the Gly18 and Pro19 peptide 
bond formation. The peptidyl-transferase centre (PTC) of ribosome thus deviates from 
its normal function, and this is presumably precipitated by interaction between the 
nascent 2A peptide and ribosomal exit tunnel. (See section 1.3.4) A somewhat similar 
case of dysfunction of PTC is the ribosome stall induced by UL4 gene uORF2, of 
human cytomegalovirus, which, like 2A peptide, functions only with eukaryotic 
ribosome.  
 
The CMV uORF2 arrests the ribosome at the final stop codon at end of the sequence. 
However, it is evident that eRF1 recognize the stop codon of the uORF2 (Janzen et al., 
2002). In the case of 2A, the prolyl-tRNA may be also able to recognise proline codon 
at A site while not drive peptide bond synthesis, since other tRNAs can recognize 
corresponding codons in the A site at end of 2A (see inactive Pro 19 mutants in section 
3.3). Therefore, for both events the rearrangement(s) that are induced by the nascent 
chain not only prevents proper recognition of the codon in the A site but also prevents 
the reactions in the PTC at the same time. Hence question arises if a stop codon is put in 
the position 19 of 2A how does it behave? 
 
To answer this question, prior to my study Dr.Victoria Doronina, a former postdoctoral 
research associate in the laboratory, made a series of FMDV 2A mutants based on the 
construct [pro-α-facor-2A] containing FMDV 2A with Pro19 to stop mutation (P19X). 
These constructs were tested in wheat germ lysate in vitro, to determine whether 2A 
peptide with a stop codon replacing P19 was, like uORF2, also able to induce a stall of 
the ribosome.          
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The result of this assay showed that in translation reactions programmed with the P19X 
mutant, as well as G18X, the upstream product was not released, but instead nascent 
chains accumulated as stable, but RNase-sensitive peptidyl-tRNA adducts. These were 
presumed to be ribosome-nascent chain complexes, with the 2A peptide inside the 
ribosomal exit tunnel (19X/18X RNC). These complexes accumulated regardless of 
which of the three stop codons (UAG, UAA, UGA) replaced Pro19. Collectively, the 
FMDV 19X/18X 2A was suggested to be able to induce ribosome stall over the stop 
codon as uORF2 (Sharma et al., 2012). The study described in this chapter focussed on 
this finding, and investigated it further.  
 
 
The previous experiments were carried out using mRNA templates that ended at 2A, 
with 19X as the final codon. It was thus unknown from this work whether the same 
would occur, i.e. ribosomal stalling, with 2A
P19X
 internal to an mRNA. Further, the 
formation of 19X RNC was only tested with a [pro-α-factor-2AP19X] construct and 
wheat germ lysate. Therefore, here I used different constructs and lysates to determine 
whether the complex was independent of these elements. In addition, 19X mutants for 
several other 2A sequences were made, to determine whether this complex was unique 
for the FMDV 2A sequence or a common feature for all 2A peptides.  
 
 
The second part of this chapter describes confirmation that 19X RNC indeed 
accumulate, and steps towards purification of these complexes. Stable formation of a 
complex is a key prerequisite for characterisation of its structure via techniques such as 
cryo-electron microscopy. Finding of 19X RNC offered a good start point for such 
analysis and for determining such things as the conformation that 2A peptides adopt 
within the exit tunnel, and the effects of the peptide on ribosome structure during the 2A 
reaction. Therefore, attempts were made to separate the complex from in vitro 
translation reactions in which they had been generated. The stability of the 19X 
ribosome nascent chain complex was examined, and efforts made to improve both the 
construct used for in vitro translation and the purification strategy. Results of these 
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experiments are presented here, along with a preliminary experiment of the purification 
of the complex.     
 
 
6.1 The formation of the 19X-RNC is independent of downstream sequence, is not 
affected by changing upstream context and occurs in different translation systems 
 
While the 19X-dependent ribosome stall found by Dr.Victoria Doronina was striking, 
the study had some limitations. Most significant one of these was that the construct she 
used in these experiments was a truncated [pro-α-facor-2A] without the downstream 
coding region to the 2A sequence. Hence, the mutual effects of the formation of the 
P19X-RNC and the presence of the downstream coding region needed further study 
Such a study would reveal, on the one hand, whether the P19X induced ribosome stall 
would still occur in presence of the downstream coding region and on the other hand, 
what would happen to the ribosome once the pause was overcome would termination 
and ribosome dissociation occur, or would the ribosomes be able to re-initiate 
translation of downstream sequences after releasing the upstream product. Alternatively, 
would ribosomes read through the stop codon and continue into the downstream 
sequence. 
 
 
6.1.1 A 19X codon directs ribosome stalling in the presence of downstream coding 
sequence, and is independent to the translational assay and construct 
 
To investigate whether ribosomes stall on a 2A with a stop codon substituted for G18 or 
P19, as seen in the experiments with truncated mRNAs, the same set of 2A mutations 
examined by Dr. Doronina (in Sharma et al., (2010)) namely P17X, G18X, P19X, P17A, 
P17A+P19X) were inserted into the plasmid pLH135 encoding [CFP-2A-PAC], which 
was previously used in chapters 3~5, with the protocol described in section 3.2.3. The 
resulting pLH135 variants were then used in coupled in vitro transcription-translations 
in reticulocyte lysate, as described in section 3.2. The result of the assay is shown in 
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figure 6.1. 
# 
 
 
 
 
 
 
Figure 6.1 2A P19X mutant drives ribosomal stalling when downstream sequences are 
present. Coupled in vitro transcription-translation reactions were assembled in 
reticulocyte lysate with [S35] methionine and pLH135 containing desired 2A mutants 
generated by the method described in section 3.1.3. Reactions were resolved on a 
Nu-PAGE 4-12% Bis-Tris gel (Invitrogen) without or with (+RNaseA) prior treatment 
with ribonuclease and visualized by phosporimager, as described in section 2.6. The 
peptidyl-tRNA was marked with ‘*’; Positions of molecular weight markers run on the 
gel are shown. 
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Results obtained with the full length [CFP-2A-PAC] polyprotein and reticulocyte lysate 
were consistent with the previous experiments (Sharma et al., 2012) with truncated 
construct and wheat germ, in terms of ribosome stalling: A species ~20 kDa 
(corresponding to the molecular weight of the tRNA) larger than the released upstream 
product was seen with the mutant P19X (lane 1). A similar, though faint, product was 
also seen with G18X (lane 2). That this represented the peptidyl-tRNA adduct was 
confirmed through its sensitivity to RNaseA, as the species shifted to the size of 
upstream product (CFP-2A) after RNaseA was added (compare lane 1,2 and lane 7,8). 
These data collectively suggested that during the translation of [CFP-2A-PAC] with 
P19X, a significant proportion of ribosomes stalled unable to release the upstream 
product. While the G18X mutant was also able to drive this stall, it was much less 
efficient in the context of further RNA sequences than when truncated mRNAs were 
used, most ribosomes terminating at the stop codon. Overall, the data obtained in these 
expeirments confirmed that the P19X and G18X-directed ribosome stall was also able 
to occur in presence of downstream coding region, and in the reticulocyte lysate. 
 
As in the study of Dr. Doronina, the peptidyl-tRNA adduct was seen in neither the 
translation sample of P17X, (lane 3) that released upstream product as normal 
transcripts ended with stop codon; nor in that of P19X+P17A (lane 4), a inactive 2A 
mutant having a stop codon at the end. These observations suggested that the stall was 
the result of effects of the amino acids of 2A position 1~17, and might follow the same 
mechanism of 2A reaction.   
 
 
In conclusion, the results presented in Figure 6.1 suggest that, the downstream coding 
region does not impair the P19X and G18X 2A mutant-induced ribosome stall, or at 
least not in a high degree; and with the stop codon at the end, 2A sequence is not able to 
carry on the translation of downstream product. Mostly likely, after the stall and release 
of the upstream product, the ribosome drops off at the final termination codon of 2A 
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mutant.  
 
For further examining the universality of P19X induced translational stall to the 
different assay and lysate, as well as optimizing the conditions for following research, 
the same construct [CFP-2A-PAC] (plasmid pLH135) containing three mutants, namely 
P19X, P19X+P17A, and P17A, were also tested in in vitro translation assay of 
reticulocyte and wheat germ lysates, using mRNA, rather than DNA, as template.  
 
For generating the mRNA templates, the pLH135 of these variants were linearized by 
Sal I, then in vitro transcription were carried out, following the protocol described in 
section 2.6.2. The resulting mRNAs were then used in in vitro translation assay of 
reticulocyte and wheat germ lysates (protocols in section 2.6.3 and 2.6.4 respectively).  
The result of these experiments is presented in figure 6.2  
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Figure 6.2 In vitro assay of 2A P19X and other mutants in wheat germ (a) or 
reticulocyte lysate (b).  In vitro translation reactions were assembled in lysates 
indicated with [S35] methionine and mRNA. Reactions were resolved on a Nu-PAGE 
4-12% Bis-Tris gel (Invitrogen) without or with (RNase+) prior ribonuclease treatment 
and visualized by phosporimager, as described in section 2.6. Peptidy(2A)-tRNA was 
marked with  ‘*’ The positions of molecular weight markers run in the gel are 
indicated. 
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The in vitro experiments using mRNA as templates obtained the similar results to the 
coupled assay. In reticulocyte lysate, the products from the mRNAs were same as in the 
coupled experiments: the same RNase-sensitive adduct, representing the upstream 
product-tRNA adduct, was observed in the same mutant (19X), at the identical size, and 
in the similar proportion with the released upstream products (compare figure 6.2b lane 
1 and the figure 6.1 lane 1). Other three mutants also behave as the previous experiment: 
the 17A+19X mutant generated no adduct, while wild type 2A and 17A inactive 2A 
mutant presented the separated and full length products respectively. On the other hands, 
the assay with the wheat germ lysate also gave the same result. Here, the 19X mutant 
indeed produced the adduct, which was, in the experiment presented degraded slightly 
(6.2a. lane 1). In these experiments using mRNA to program the translation reactions, 
no 25 kDa species was seen in when 2A mutants were used (compare with Fig 6.1). The 
same set of mRNAs were also tested in the third lysate used in this chapter, the yeast 
extract. However, in this case, the in vitro assay failed to generate any detectable signal 
(Data not shown). 
 
In summary, the data obtained is this section combined with that of Dr. Victoria 
Doronina, (truncate construct [polyhis pro-α-facor-2A], with wheat germ lysate) suggest 
that 19X-depentent ribosome arresting and is independent to the construct, lysate and 
template.  
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6.1.2 Ribosome stalling directed by P19X occurs with different 2A peptides 
 
The study of P19X dependent ribosome arresting carried out so far was all based on the 
mutants of 2A sequence from FMDV. As discussed in the chapters of mutagenesis study, 
the different 2A sequences, especially the positions 1-11, may adopt different strategies 
to function. It was therefore important to ask whether a ribosomal stall at a P19X 
mutation could also occur in other 2A peptides besides FMDV. Hence, in this section, 
the mutation P19X was made to other 2A sequences to test its ability to arrest the 
ribosome in alternative 2A contexts.  
 
Three 2A sequences besides FMDV were selected for this study. These were from 
Theiler's murine encephalomyelitis virus (TMEV), infectious myonecrosis virus (IMNV) 
and pseudorabies virus (Prv-1) TMEV 2A is a representative of His11 type of 2As, 
while the IMNV and Prv-1 2A peptides have very different amino acid composition to  
FMDV 2A, and do not display the strong α-helical propensity within their N-terminal 
portion. All three 2A sequences have high activity in previous study using the 
[GFP-2A-GUS] construct (Donnelly et al., 2001). The version of TMEV 2A contained a 
M15S mutation, which, as discussed in chapter 5, should be a neutral change that not 
affects the 2A function. The sequences of these 2A peptides were presented in table 6.1 
column ‘sequence’.  
 
 
Host virus Sequence 
FMDV(start plasmid) TLNFDLLKLAGDVESNPGP 
TMEV(S15M) HADYYKQRLIHDVESNPGP 
Prv-1 VGGRGSLLTCGDVESNPGP 
IMNV MLPPPDLTSCGDVESNPGP 
 
Table 6.1 the sequence of 2A peptide tested in this section 
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The selected 2A sequences were generated and inserted into plasmid pJN275M4 via the 
method described in section 5.2.1. pJN275M4 is a variant of pJN141 that Dr. Doronina 
used in previous study (Sharma et al., 2012) (see section 6.2.1), and contains 
[pro-α-factor-2A-prolactin] preceeded by a 8xHIS-tag.  
 
The three resulting plasmids, after linearized by restriction enzyme PvuII, were 
transcribed with SP6 in vitro, and the resulting mRNAs were tested in in vitro 
translation assay using wheat exacts. The samples of the translation were resolved on a 
Nu-PAGE 4-12% Bis-Tris gel (Invitrogen) and visualized by phosporimager (protocol 
see section 2.6). All the selected 2A sequences, including the M15S-mutated TMEV, 
gave high level of 2A activities with the reporter, and were therefore characterized as 
functional 2A sequence (Data not shown). This also conforms the previous finding and 
extends it to the different context, i.e. of the alpha factor fusions. 
 
To examine whether P19X mutants of three selected 2A sequences were able to induce 
ribosomal stalling, two truncated constructs containing wild type sequence and mutant 
P19X ([polyhis tag-pro-α-facor-2A] and [polyhis tag-pro-α-facor-2AP19X]) were 
generated from the constructs containing each one of these 2A peptides, along with the 
FMDV peptide as a positive control. The strategy used here to generate truncated 
constructs was one of the basic methods of the study described in this chapter and used 
excessively in the research described in section 6.2. Hence, a more detailed introduction 
on this method is presented here: 
 
For making the mutants, the oligonucleotides comprising the reverse 2A sequence with 
desired changes (in this case, P19X or wild type) were designed. Then, touchdown PCR 
was performed, as described in Methods and Materials section 2.4.3, with the above 
oligonucleotide and an SP6 promoter primer, and plasmid pJN275M4, that contains SP6 
promoter followed by the open reading frame, as template. Thus, the resulting PCR 
fragment of coding sequence of [polyhis tag-pro-α-facor-19X/WT] was generated. 
Using this fragment as template, in vitro transcription with 5’cap analog was applied, as 
described in section 2.6.2. Finally the 5’-capped mRNA of the construct 
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[pro-α-facor-desired 2A mutant] is obtained, and used in following in vitro translation 
test with various lysate systems. (Figure 6.3)  
 
 
 
. 
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Figure 6.3 General strategy of the generation of truncated 2A mutants. See text for 
details  
 
 
 
 
The mRNA ended with P19X mutant and wild type of the three selected 2A peptides 
and FMDV 2A were generated as the strategy described above, and tested by in vitro 
assay of wheat germ lysate. The result of the assay is shown in figure 6.4 
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Figure 6.4 The P19X mutation directs ribosome stalling in the context of different 2A 
sequences.Truncated mRNA was prepared from plasmid pJN275M4 variants containing 
2A sequences from FMDV, IMNV, Prv-1 and TMEV. In vitro translation reactions were 
assembled in wheat germ with [S35] methionine and the mRNA. Reactions were 
resolved on a Nu-PAGE 4-12% Bis-Tris gel (Invitrogen) without or with (RNase+) prior 
treatment with ribonuclease, and visualized by phosporimager, as described in section 
2.6. Peptidy(2A)-tRNA was marked with  ‘*’ Positions of molecular weight markers 
run on the gel are shown. 
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Results obtained from different 2A peptides were very similar. The adducts ~40 kDa 
representing the peptidy-tRNA presented with the P19X mutants based on all four 2A 
sequences (lanes 1 to 4). As expected, these adducts were RNaseA-sensitive. (compare 
lanes 1 to 4 and 5 to 8) On the other hand, in the sample of all 4 wild type 2A sequence, 
the majority of translation yield was the upstream products with the predicted size of 
expected from their sequence (lanes 9 to 12). Notably, the ~40 kDa, RNaseA-sensitive 
adducts, albeit faint, were also seen with wild type 2A sequences. This species was 
observed in the previous study (Sharma et al., 2012). This can be explained as the 
representative of the ribosome stall induced by non-stop open reading frame: of wild 
type 2As the separation activities never reached 100 %, which means that small 
proportion of ribosomes are passing the 2A sequence and continuing translate to 
generate full length product rather than ‘trapped’ into the 2A reaction; similarly, during 
the translation of the truncated construct ended with wild type 2A, minority of ribosome 
‘escaped’ from the 2A mechanism, and as the construct has not stop codon, they are 
stalled by the non-stop mRNA. An argument in favour of this explanation is that the 
amount of the ~40 kDa, RNaseA-sensitive adducts in the sample of a wild type 2A, is 
roughly inversely proportional to the separation activity of the 2A.              
 
These observations agree with the argument that, the P19X mutation induced ribosome 
stalling are the same as FMDV 2A with other three 2A sequences, and, though I have 
not tested an exhaustive set of 2A peptides with P19X, the data obtained with the 4 
peptides, which have very varied amino acid sequence, suggest that it may be a 
phenomenon that would occur with all 2A peptides. 
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6.2 Purification of the 19X directed ribosome nascent chain complex 
 
 
As shown in the section 1.2.4 (introduction), in studies of translation-arrested peptides, 
cryo-EM has generated some of the most insightful data in recent years. 2A peptides 
also pause the translation during 2A reaction (section 1.3), but this pause is very short 
(Doronina et al., 2008), making it infeasible to investigate by cryo-EM, which requires 
the purified ribosome particle with the nascent peptide inside its exit tunnel. The P19X 
mutant provides, for the first time, a substrate that may be sufficiently stable to purify 
for structural analysis. This section describes the generation, optimization and a 
preliminary purification of 19x RNC with the ribosomes stalled on a P19X 2A mutant. 
        
 
 
6.2.1 Construct of the template for the purification 
 
The construct selected to be used in purification experiments was based on the truncated 
[pro-α-facor-2A-pLL] with 2A P19X, that was similar to the one used in section 6.1.2 
and previous study. This provided a nascent chain length of ~70 amino acids, which 
guarantees that when P19X-induced translation stall occurs, the N-terminal end of the 
nascent chain has emerged from the ribosomal exit tunnel (which can hold the length of 
~40 amino acids in compacted form). Thus, a ‘tag’ suitable for purification can be added 
to the N-terminal end. On the other hands, though the effect of the length of the nascent 
chain to the stall complex is largely unclear, any excessive amino acids on the peptide 
chain might impair the stability of the complex. The use of the truncated construct 
ensured that all the stalled ribosomes would be at P19X – ribosomes either terminate or 
stall at this mutation (See Figure 6.1 and 6.2).  
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Prior to my study, a poly-His tag was added to the N-terminal end of construct 
[pro-α-facor-2A(FMDV)-pLL] in the plasmid pJN141, which Dr. Doronina used in 
previous study (Sharma et al., 2012), for the purification of P19X RNC using his-tag 
affinity Ni resin. I generated His-tagged truncated construct [pro-α-facor-2A] from the 
resulting plasmid (pJN275) with the method described in section 6.1.2, and examined it 
in vitro. However, besides the expected species ~12 kD representing the translation 
product, (Figure 6.5 a lane 2, marked with ‘*’) a prominent ~9 kD species was also seen 
when the reaction was treated with RNaseA (Figure 6.5 a lane 2, marked with red‘*’). 
Given its size, and the position of methionine codons in the coding sequence of the 
mRNA, this was suspected to be the product of translation in which the ribosome 
‘skipped’ the start codon of the mRNA, started at the second methionine to the 
N-terminal end. Indeed, in plasmid pJN275, the start codon is very close to the SP6 
promoter, i.e. 5’-end of the mRNA. Such a short distance can cause ribosomes to miss 
the start codon. As the poly-His tag was added just after the first methionine codon, 
skipping of the start codon meant a large proportion of constructs translated would not 
contain the tag.  
 
To overcome this problem, a spacer 80 nucleotides sequence was inserted (through 
EcoRI) between the SP6 promoter and the start of the open reading frame, (using the 
strategy described in section 5.2.1). This space both extended the distance of start codon 
to the 5’-end of mRNA, but also placed the start codon the Kozak consensus sequence 
(GCCACCATGG) that facilitate efficient initiation. Translation of mRNA from the 
resulting plasmid (pJN275M4), (Figure 6.5B) revealed the majority translation product 
(after RNaseA treatment) to be 12 kDa. The conclusion reached was that the the start 
codon was being efficiently recognised, and therefore the plasmid pJN275M4 was 
selected as the starting construct for further experiments.  
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Figure 6.5 The optimization of construct [pro-α-facor-2A]. Truncated mRNA containing 
FMDV P19X mutant was prepared from plasmid pJN275 and pJN275M4 containing 2A 
In vitro translation reactions were assembled in wheat germ with [S35] methionine and 
the mRNA. Reactions were resolved on a Nu-PAGE 4-12% Bis-Tris gel (Invitrogen) 
without (1) or with (2) prior treatment with ribonuclease, and visualized by 
phosporimager, as described in section 2.6. Positions of molecular weight markers run 
on the gel are shown. See text for detail 
 
 
 
 
Besides the construct, wheat germ lysate was chosen as the best system to generate the 
P19X RNC. In parallel experiments this provided the best yield and stability of the 
complex (data not shown) 
 
 
 
 
 133 
6.2.2 Preliminary purification of the P19X RNC 
 
 
After generation and testing of plasmid templates and selection of the lysate, a 
preliminary purification experiment was carried out. This experiment followed a 
protocol adapted from (Halic et al., 2004), and which is described in the Materials and 
Methods (section 2.7). There were two main steps in this method following the 
translation reaction itself. The first step is sucrose gradient centrifugation, in which 
ribosomes (including RNCs), are centrifuged into a pellet thereby separating them from 
the rest of the sample. The pellet is then resuspended in buffer and the second 
purification step is immobilised metal ion affinity chromatography on Ni-NTA agarose. 
This affinity purification step should specifically isolate the RNC carrying the 
His-tagged RNC from, other ribosomes as well as other pelleted material.(see section 
2.7 for details)            
. 
  
Three truncated 2A variants were selected as the subjects for a prelimianry purification 
experiment: FMDV-P19X and FMDV wild type, both generated from pJN275M4, with 
the wild type sequence and FMDV-P19X generated from pJN141, which contained 
untagged [pro-α-facor-2A-pLL]. The wild type 2A acted as a control that released the 
nascent chain, which should then not be present in the pellet of sucrose gradient 
centrifugation. The untagged P19X product should remain ribosome associated, but not 
purify on the Ni-NTA resin. Truncated mRNAs were generated from the templates 
amplified from respective plasmids, with the method described in section 6.1.2. These 
mRNAs were then assembled with the wheat germ extracts and [S35] methionine for in 
vitro translation, and the centrifugation and affinity purification steps followed. After 
purification, the beads used to bind the complex were heated in loading dye, at 80℃ for 
5 mins to release any material remaining associated with the beads following the elution 
steps, Fractions derived from each step of the protocol were then separated on a 
Nu-PAGE 4-12% Bis-Tris gel (Invitrogen) and visualized by phosporimager. The result 
of this experiment is presented in figure 6.6 
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Figure 6.6  Purification of the 19x RNC. w, x, c refer to FMDV-wt, FMDV-19x (both 
His-tagged), and FMDV-19x from pJN141 respectively, see text for details  a. the 
sucrose centrifuge: the F, C-S, C-P, R-S refers to full reaction, centrifuge-supernate, 
resuspended  centrifuge-pellet and binding supernate respectively. b. beads of poly   
His-tag purification: Wash, W-I, Elu-X1, Elu-X2, refer to the elution from the beads 
washed with buffer containing 250 and 500 potassium acetate, 10mM imidazole, 
100mM imidazole, 200mM imidazole, respectively. ‘Boil’ refer to material released 
from the beads following heating. See text and section 2.7 for details. The 
peptidy-tRNA adduct representing the 19X-RNC, is marked with ‘*’  
 
 
The result of sucrose gradient centrifugation is generally positive. In the in vitro 
translation, the 2A mutants generated the products as expected. The two P19X mutants 
gave a relatively low proportion of released peptide, (a. lanes 2 and 3) compared to the 
wild type 2A where most of the nascent chains were released. (a. lane 1) 
Peptidyl-tRNAs were clearly isolated in the pellet following sucrose gradient 
centrifugation, as there was no adducts representing the P19X-RNC (or non-stop mRNA 
induced RNC in the case of wild type 2A, see section 6.1.2) can be seen only in the 
resuspended pellet, in which very small amount of released peptide detected; (a. lanes 
7~9) on contrast no adduct but only peptides can be found in supernate.(a. lanes 4~6) 
 
Subsequent purification on Ni-NTA resin was less successful. The similarity of the 
amount of P19X RNC in supernate between before and after the Ni-NTA beads binding 
in two his-tagged mutant, (w,x) indicated low binding efficiency; (compare a. lanes 7,8 
with 10,11) and during and after the binding, a high proportion of the nascent chains 
were released from the complexes (or degraded), implying that the binding condition 
itself was not favour able to the stability of the complex. Indeed, after removal of the 
unspecific binding by wash (b. lanes 1~6), only a very small amount of intact RNCs 
were eluted from the beads (lanes 7~12). However, this was specific, as the specific 
elution was only detected with two his-tagged mutants (b. lanes 7,8,10,11) but not the 
untagged control. (b. lanes 9,12) 
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6.3 Summary and discussion 
 
The study discussed in this chapter extends the finding of FMDV 2A mutants P19X and 
G18X-induced ribosome stall to different translation systems and constructs. The 
evidence that this stall could occur in presence of downstream coding region is also 
provided (section 6.1.1, Figure 6.1). However comparison with Dr. Doronina’s data 
revealed that a larger proportion of the upstream product was seen with the P19X in the 
construct [GFP-2A-PAC] than the same mutant in truncated constructs [pro-α-facor-2A]. 
This indicated here the P19X-RNC is less stable than the previous study. As in the 
wheat germ lysate used in previous study, like reticulocyte lysate, also gave the high 
level of released peptide with P19X (Figure 6.2), this can not be a result of the different 
lysates. Therefore, there are only two possible reasons for the lower stability of the 
complex in present experiment: 
 
1) The presence of mRNA sequence downstream to the 2A does influence the 
P19X-induced ribosome stalling. Although the stalling still occurs, the length of the stall 
is shorted.  
 
2 ) The stability of P19X-RNC is also affected by the upstream context.  
 
On the other hand, the presenting the stop codon in the final position of 2A sequence 
has been proved being able to remove the re-initiation of 2A of the translation. This 
confirmed that the two main events of 2A function, the non-stop codon releasing and the 
re-initation of translation are coupled, rather independent process. 
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Chapter7 Summary and discussion 
 
 
The 2A reaction comprises two main unconventional events during translation: 
ribosome releasing the upstream product at end of the sequence without a stop codon, 
and re-initiation of the translation of downstream coding region, with Pro19 as the start 
codon. While the mechanism of the re-initiation is almost totally unknown (though it is 
generally believed coupled with the first event), a model, suggested by the current 
research, has been proposed to explain the non stop codon releasing. According to this 
model, the amino acids located at position 1~17th of 2A sequence, through interaction 
with the ribosomal components, directs the peptidyl transferase centre of ribosome 
deviating its normal function, thus, while the PTC can still catalyse the peptide bond 
formation for other amino acids pairs, it is not able to generate the bond between proline 
and glycine at the 18th and 19th position of 2A, which is the most demanding amino 
acids pair for peptide bond formation. Therefore, the study described in this thesis 
including two themes: 
 
1) Site-specific mutagenesis study of 2A sequence, for investigating the functional 
elements within 2A sequence and detecting the potential interaction between the 2A 
nascent chain and ribosomal exit tunnel;   
 
2) Analysis of the finding of 2A peptides with Pro19 and Gly18 to stop codon mutation, 
which direct the ribosome stalling during the translation. This not only reveals, 
potentially due to the effect of position 1~17 of 2A, the dysfunction of PTC of ribosome, 
but also give a profound perspective for the further cryo-EM study. 
 
 
Originally as a complimentary study to a previous 2A random mutant screen, the 
site-specific mutagenesis was carried out to the whole sequence of 2A. The mutants, 
except ones that largely deviated from the sequence of FMDV 2A, was generated by the 
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site-specific PCR described in section 3.1. In present study, the separation activity of 2A 
mutant were examined by two independent reporter system: an in vivo assay that 
exploited the varied colour (white to red) of yeast expressing reducing amounts of 
Ade2p and an in vitro translation assay using the poly-protein construct [GFP-2A-PAC] 
(pLH135). The in vivo assay for Val13 and Gly11 of 2A sequence filled the ‘holes’ of 
the previous random screen. The result found that all mutations at these two positions 
reduce the 2A activity dramatically, and therefore there are strict constrains for the 13 
and 11 position. This result, combined with previous data obtained from the random 
screen, suggests the whole 19 amino acid in 2A sequence, despite the variability of the 
N-terminal portion, is less flexible than expected. Thus, unlike many other peptides 
manipulating the translation process, the amino acids in the whole 2A sequence 
participate the reaction in some way.  
 
Many of the 2A sequences, including the one from FMDV, have strong α-helical 
propensity on their N-terminal portion. For examining whether the secondary structure 
α-helix was critical for the 2A function, as well as addressing the general duration 
pattern of the positions in 2A sequence against mutations, three amino acids, alanine, 
proline and glycine, that have the different α-helical propensity, were systematically 
substituted into each position of FMDV 2A sequence, then tested by coupled in vitro 
assay in reticulocyte lysate. Among three sets of mutants, similar trend was observed: 
the closer a position is to the C-terminal end, the more serious impairment that results 
from the substitution, with only one major exception of position 15. This result 
coincides with previous 2A alignment study, suggest that the positions close to the 
N-terminal end are less demanding than that of C-terminal end. Indeed, among all 11 
mutations at first two positions to the C-terminal end examined by present study and 
previous random screen, only 2 of them (L1P, L1Q) showed obvious activity decrease. 
Hence, the contribution of amino acids at position 1 and 2 may be simply excluding 
certain unfavorable amino acids and setting good context for the 2A peptide. On the 
other hand, as the distinct secondary structure propensity of proline glycine and alanine, 
the resemblance of the general trend presented by the systematical replacement screen 
with this three amino acid implies that α-helical propensity previously thought critical 
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for the 2A function might not be crucial, or at least that the structure of the backbone 
alone could not satisfy the requirement(s) of 2A function at most positions, other factors 
such as side chain must be considered. 
 
The abundant information collected from the mutagenesis study, as well as structural 
studies of other peptides manipulating the translational process allows us to estimate the 
potential interactions between nascent chain of 2A and the ribosomal component within 
the exit tunnel. The preliminary estimation is discussed in this final section. The 
structural study using cryo-EM method of two eukaryotic ribosomal arresting peptides, 
Cytomegalovirus UL4 uORF2 and arginine attenuator peptide (AAP), reveals that the 
both peptides contact the ribosomal proteins L4/L17 emerging from wall of the 
constriction region of the exit tunnel, with their 10th (Ser12 of uORF2) and 12th (Asn12 
of AAP) amino acids counted from PTC. The mutagenesis studies of uORF2 and AAP, 
as well as many other structural and biochemical studies on ribosome stalling peptides 
of prokaryotic translation, confirm such contacts critical for the function of these short 
peptides, and that they are the most common interactions that the peptides driving 
translation may apply. According to corresponding length of amino acids chain of 2A 
sequence to that of uORF2 and AAP, the 2A peptide, if it also interacts with the rprotein 
in the exit tunnel constrain region, it may interact with these rproteins with its amino 
acid(s) located at position 6~9. Since during the reaction the both of uORF2 and AAP 
adopt compact form within the exit tunnel, providing the 2A adopt a looser 
conformation, the amino acid interacting with the ribosomal components may also be 
the one at position 11, the importance of which has been proved by the mutagenesis 
study presented in this study. If it is the case, it will be a reasonable explanation to the 
finding that the 2A peptides with glycine or histidine at position 11 having distinct 
strategy to drive 2A reaction. 
 
The structural study of AAP and uORF2 also reveals the extensive interactions of the 
C-terminal half of these short peptides with the nucleotides of the wall of the upper 
tunnel region of the exit tunnel. This might also happen during the 2A reaction. While 
the mutagenesis study suggests in AAP and uORF2 some of these contacts may not be 
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critical, for the 2A reaction the potential contacts between the C-terminal portion and 
rRNA should be important, as the data presented in this and previous study shows that 
any change on the sequence of the conserved C-terminal portion, except position 15, 
dramatically impairs, or abolishes the separation activity. 
 
During the 2A reaction, the N-terminal portion of 2A sequence mainly rests in the lower 
tunnel region of the exit tunnel. A possible explanation of its function is to correctly 
position the conserved C-terminal portion including position 11, for facilitating their 
potential interactions with ribosomal component. 
 
 
 
The second theme of the study presented in this thesis is the analysis of the P19X and 
P18X 2A mutants-induced translation stalling. A previous mechanism research revealed 
that, a construct ending with FMDV 2A mutants P19X and G18X directed the ribosome 
stalling during the translation process, forming the so called P19X/G18X directed 
ribosome nascent chain complex (P19X/G18X RNC). This previous research used 
truncated construct with no downstream coding region to 2A. Here I found that the stall 
still occurred, though in a compromised level, in presence of the downstream sequence; 
and that with the P19X/G18X, the translation of downstream sequence to 2A is failed to 
be re-initiated. The P19X-induced ribosome stalling was also examinied with different 
construct and in vitro translation lysates, and 2A peptides from different origins. The 
results showed this stall, though in variable levels, occurred in all conditions that were 
been tested. These observations extend this finding, suggesting that the stalling is 
independent to the construct, lysate used in the test, and is universal among all the 
functional 2A peptides.  
 
The P19X/G18X-induced ribosome stalling offers further evidence that the sequence of 
the position 1~17 of 2A directs the ribosomal peptidyl-transferase centre into 
dysfunction, presumably through the potential interactions between the nascent chain 
and ribosomal components. Moreover, it also provides a profound perspective for 
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further structural analysis. During the 2A reaction there is indeed a short pause, but this 
is too short for cryo-EM study. Here providing that the wild type 2A and 
P19X/G18X-induced ribosome stalling follows same mechanism to disturb the function 
of the PTC, the structural insight of 2A peptide can be obtained through the cryo-EM 
analysis for P19X-RNC, which is stable enough to be tested by the technique. For this 
purpose, a construct had been built (pJN275M4) and preliminary purification of the 
P19X-RNC was preformed. However, the experimental conditions need further 
optimization to meet the requirement of cryo-EM study. 
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